var title_f12_15_12528="MRI pediatric MS";
var content_f12_15_12528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    MRI pediatric multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Axial FLAIR MRI demonstrating periventricular well-demarcated lesions. B) Axial T1 from the same patient demonstrating a black hole in the right centrum semiovale.",
"    <div class=\"footnotes\">",
"     FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12528=[""].join("\n");
var outline_f12_15_12528=null;
var title_f12_15_12529="Antiseptic mouthwash (dental): Drug information";
var content_f12_15_12529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antiseptic mouthwash (dental): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimicrobial Mouth Rinse;",
"     </li>",
"     <li>",
"      Antiplaque Agent;",
"     </li>",
"     <li>",
"      Mouthwash",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Plaque/gingivitis prevention:",
"     </b>",
"     Oral: Rinse full strength for 30 seconds with 20 mL morning and night",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F198224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rinse: 250 mL, 500 mL, 1000 mL",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15162769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aid in prevention and reduction of plaque and gingivitis; halitosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4088907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Corsodyl Mouthwash (PL)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9031 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12529=[""].join("\n");
var outline_f12_15_12529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198229\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198223\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198224\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162769\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198227\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198221\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4088907\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12530="Moro reflex";
var content_f12_15_12530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Moro reflex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 645px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The moro reflex is present starting at 32 weeks gestation and disappears by three to six months of age. It is elicited by the sudden dropping of the infant's head in relation to the trunk and results in abduction and extension of the infant's arms and opening of the hands, followed by flexion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12530=[""].join("\n");
var outline_f12_15_12530=null;
var title_f12_15_12531="Patient information: Planning for a kidney transplant (The Basics)";
var content_f12_15_12531=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16442\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37809\">",
"          Kidney transplant",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/42/19107\">",
"         Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/1/25619\">",
"         Patient information: Hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/43/16051\">",
"         Patient information: Peritoneal dialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/44/35523\">",
"         Patient information: Polycystic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/22/11619\">",
"         Patient information: Preparing for hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/26/9635\">",
"         Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/57/40852\">",
"         Patient information: Hemodialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/10/14501\">",
"         Patient information: Peritoneal dialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/24/38277\">",
"         Patient information: Polycystic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Planning for a kidney transplant (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/planning-for-a-kidney-transplant-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16551971\">",
"      <span class=\"h1\">",
"       What is a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A kidney transplant is a surgery to insert a new, healthy kidney into a person whose kidneys are diseased. Normally, the kidneys filter the blood and remove waste and excess salt and water (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). When people have kidney failure, also called &ldquo;end-stage renal disease,&rdquo; their kidneys stop working.",
"     </p>",
"     <p>",
"      During a kidney transplant, a doctor puts a healthy kidney in a person&rsquo;s body (",
"      <a class=\"graphic graphic_figure graphicRef59957 \" href=\"UTD.htm?36/59/37809\">",
"       figure 2",
"      </a>",
"      ). Then the new kidney can do the job of the diseased kidneys. (People need only 1 kidney to live.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16551986\">",
"      <span class=\"h1\">",
"       Where can a new kidney come from?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A new kidney can come from a:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Living donor &ndash; A living donor is usually a family member or friend. He or she can be related to you, but doesn&rsquo;t need to be. A living donor can also be someone you don&rsquo;t know, but this is not as common.",
"       </li>",
"       <li>",
"        Dead donor",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Getting a new kidney from a living donor is almost always better than getting a kidney from a dead donor. That&rsquo;s because:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A kidney from a living donor is usually healthier and lasts longer.",
"       </li>",
"       <li>",
"        You don&rsquo;t have to wait as long for a new kidney. You can get a new kidney before your kidneys stop working completely.",
"       </li>",
"       <li>",
"        Your body is more likely to react better to a kidney from a living donor.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16552001\">",
"      <span class=\"h1\">",
"       When should I plan for a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should start planning while your kidneys still work and before your kidney disease gets severe. You will need time to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Find a living donor (if you want a living donor)",
"       </li>",
"       <li>",
"        Meet with doctors and have the exams and tests you need before surgery",
"       </li>",
"       <li>",
"        Get information and make plans &ndash; You should find out if your health insurance will pay for the transplant. You might need to make plans for when you are in the hospital and away from your job or family.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16552016\">",
"      <span class=\"h1\">",
"       How do I plan for a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, your doctor will send you to a transplant center. At the transplant center, you will meet with different doctors and have exams and tests.",
"     </p>",
"     <p>",
"      Not everyone who wants a kidney transplant can get one. People usually can&rsquo;t have a kidney transplant if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have severe heart disease or another serious long-term illnesses",
"       </li>",
"       <li>",
"        Have cancer or recently had cancer",
"       </li>",
"       <li>",
"        Are too overweight",
"       </li>",
"       <li>",
"        Can&rsquo;t or won&rsquo;t take medicines every day after surgery",
"       </li>",
"       <li>",
"        Drink too much alcohol or use drugs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The person who wants to donate a kidney also needs to go to a transplant center. He or she needs to meet with doctors and have exams and tests. To donate a kidney, a person needs to be healthy and meet certain conditions. His or her blood also has to match the blood of the person getting the kidney. The person getting the kidney is called the &ldquo;recipient.&rdquo;",
"     </p>",
"     <p>",
"      It&rsquo;s important to know that the results of the donor&rsquo;s exams and tests are kept secret. Plus, he or she can change his or her mind about donating at any time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16552031\">",
"      <span class=\"h1\">",
"       What if I don&rsquo;t have a living donor or my living donor isn&rsquo;t a good match?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you don&rsquo;t have a living donor or your donor isn&rsquo;t a good match, you have a few options.",
"     </p>",
"     <p>",
"      You can be put on a list to get a kidney from a dead donor. An organization called &ldquo;UNOS&rdquo; keeps track of this list. When a new kidney is available, UNOS decides who is next on the list to get it.",
"     </p>",
"     <p>",
"      One downside to being on this list is that you need to have very severe kidney disease to get to the top of the list. While you are waiting for your kidney transplant, you will probably need a treatment called &ldquo;dialysis.&rdquo; People who need to have dialysis before a kidney transplant usually don&rsquo;t live as long as people who don&rsquo;t need to have dialysis before a transplant.",
"     </p>",
"     <p>",
"      If you have a living donor, but he or she isn&rsquo;t a good match for you, you can look for an &ldquo;exchange program.&rdquo; One type of exchange program is called a &ldquo;paired exchange.&rdquo; In a paired exchange, you and your donor find another donor and recipient who don&rsquo;t match each other, but do match with you. Then your donor can give a kidney to the other recipient, and the other donor can give a kidney to you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16552046\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=see_link\">",
"       Patient information: Polycystic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"       Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       Patient information: Hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"       Patient information: Preparing for hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"       Patient information: Peritoneal dialysis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=see_link\">",
"       Patient information: Polycystic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       Patient information: Peritoneal dialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       Patient information: Hemodialysis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/15/12531?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16442 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-57354D163F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12531=[""].join("\n");
var outline_f12_15_12531=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16551971\">",
"      What is a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16551986\">",
"      Where can a new kidney come from?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16552001\">",
"      When should I plan for a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16552016\">",
"      How do I plan for a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16552031\">",
"      What if I don&rsquo;t have a living donor or my living donor isn&rsquo;t a good match?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16552046\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37809\">",
"       Kidney transplant",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=related_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12532="Pralidoxime: Pediatric drug information";
var content_f12_15_12532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"32\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pralidoxime: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16517?source=see_link\">",
"    see \"Pralidoxime: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/31/23027?source=see_link\">",
"    see \"Pralidoxime: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Protopam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Anticholinesterase",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Organophosphate Poisoning",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16517?source=see_link\">",
"      see \"Pralidoxime: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in conjunction with atropine; atropine effects should be established before pralidoxime is administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Organophosphate poisoning:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     I.V. administration is preferable; if I.V. route not feasible, may be given I.M. or SubQ",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants, Children, and Adolescents &le;16 years: Loading dose: 20-50 mg/kg (maximum: 2000 mg/dose); Maintenance infusion: 10-20 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; alternatively, a repeat bolus of 20-50 mg/kg (maximum: 2000 mg/dose) may be administered after 1 hour if muscle weakness is not relieved and repeated every 10-12 hours thereafter, as needed if muscle weakness persists",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &gt;16 years and Adults:  Loading dose: 1000-2000 mg; Maintenance: Repeat bolus of 1000-2000 mg after 1 hour and repeated every 10-12 hours thereafter, as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants, Children, and Adolescents &lt;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Mild symptoms: 15 mg/kg/dose; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 45 mg/kg; may administer doses in rapid succession if severe symptoms develop",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe symptoms: 15 mg/kg/dose; repeat twice in rapid succession to deliver a total dose of 45 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Persistent symptoms: May repeat the entire series (45 mg/kg in 3 divided doses) beginning ~1 hour after administration of the last injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents &ge;40 kg and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild symptoms: 600 mg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 1800 mg; may administer doses in rapid succession if severe symptoms develop",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe symptoms: 600 mg; repeat twice in rapid succession to deliver a total dose of 1800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Persistent symptoms: May repeat the entire series (1800 mg in 3 divided doses) beginning ~1 hour after administration of the last injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticholinesterase poisoning (eg, neostigmine, pyridostigmine):",
"     </b>",
"     Adults:  I.V.: 1000-2000 mg; followed by increments of 250 mg every 5 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Pediatric patients (age not specified) and Adults: Dose should be reduced; no specific recommendations are provided by the manufacturer",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protopam&reg;: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as chloride: 300 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.:  May use 300 mg/mL solution autoinjector or dilute 1000 mg vial with 3.3 mL SWI for a final concentration of 300 mg/mL; in children, administer intramuscularly in the anterolateral aspect of the thigh",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Reconstitute 1000 mg with 20 mL SWI (50 mg/mL); further dilute with NS to a final concentration of 10-20 mg/mL; maximum concentration is 50 mg/mL (in SWI) and should be used when lower concentration not practical or in cases of fluid overload, pulmonary edema or more rapid administration is needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Loading dose: Infuse over 15-30 minutes; if maximally concentrated solution (50 mg/mL) may be administered over &ge;5 minutes not to exceed 200 mg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose (intermittent infusion): Infuse over 15-30 minutes a rate not to exceed 200 mg/minute",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14790959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and chemicals (eg, nerve agents) [FDA approved in pediatric patients (age not specified) and adults]; control of overdose of anticholinesterase medications used to treat myasthenia gravis (ambenonium, neostigmine, pyridostigmine) [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pralidoxime may be confused with pramoxine, pyridoxine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Protopam&reg; may be confused with protamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (transient), AST increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection (I.M. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, fasciculations, muscle rigidity, paralysis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Accommodation impaired, blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal function decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, hyperventilation, laryngospasm",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pralidoxime or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with myasthenia gravis; administration may precipitate a myasthenic crisis. Use with caution in patients with renal impairment; dosage modification may be required. Rapid I.V. infusion may be associated with temporary worsening of cholinergic manifestations (eg, tachycardia, laryngospasm, muscle rigidity, cardiac arrest) in adults; in children muscle fasciculations, apnea, and convulsions have also been reported. During the management of anticholinesterase poisoning, the use of medications that may be potentiated by anticholinesterases; avoid use if possible or use extreme caution including theophylline, aminophylline, reserpine, succinylcholine, phenothiazines, respiratory depressants (eg, narcotic, barbiturates).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical symptoms that are consistent with suspected organophosphate poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests; treatment should include proper evacuation and decontamination procedures as indicated; medical personnel should protect themselves from inadvertent contamination. Antidote administration is intended only for initial management; definitive and more intensive medical care is required following administration. Individuals should not rely solely on antidote for treatment; the concomitant use of atropine will be necessary and other supportive measures (eg, artificial respiration) may still be required. Pralidoxime is not indicated for the treatment of carbamate poisoning; acetylcholinesterase is weakly, but not permanently, affected by carbamates. Pralidoxime is not indicated for the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates without anticholinesterase activity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13459587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. A case report did not show evidence of adverse events after pralidoxime administration during the second trimester (Kamha, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, respiratory rate, muscle fasciculations and strength, pulse oximetry, blood pressure and cardiac monitoring with I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactivates cholinesterase that had been inactivated by phosphorylation as a result of exposure to organophosphate pesticides and cholinesterase inhibiting nerve agents (eg, terrorism and chemical warfare agents such as sarin) by displacing the enzyme from its receptor sites; removes the phosphoryl group from the active site of the inactivated enzyme",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.6-2.7 L/kg; severely poisoned pediatric patients (n=11; age: 0.8-18 years): ~9 L/kg (range:1.7-13.8 L/kg) (Schexnayder, 1998); may increase with increasing severity of organophosphate intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Apparent: 74-77 minutes; pediatric patients (n=11; age: 0.8-18 years): 2.4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: 35 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~80% as metabolites and unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14790973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most effective when given as soon as possible after exposure, typically within 36 hours after termination of exposure to poison.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12720 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12532=[""].join("\n");
var outline_f12_15_12532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212244\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061315\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061310\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212224\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212210\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061319\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790959\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061318\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212271\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212269\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061322\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061309\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061308\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299930\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212218\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212220\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13459587\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061314\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061307\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061321\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790973\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12720\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12720|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16517?source=related_link\">",
"      Pralidoxime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/31/23027?source=related_link\">",
"      Pralidoxime: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12533="Docetaxel: Patient drug information";
var content_f12_15_12533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Docetaxel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     see \"Docetaxel: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14120?source=see_link\">",
"     see \"Docetaxel: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Docefrez&trade;;",
"     </li>",
"     <li>",
"      Taxotere&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Docetaxel for Injection;",
"     </li>",
"     <li>",
"      Taxotere&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to swell or keep fluid in your body. Tell your doctor if you have swelling, weight gain, or trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700370",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to docetaxel or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to polysorbate 80.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701370",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling. Your doctor may start you on a drug to stop this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10751 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12533=[""].join("\n");
var outline_f12_15_12533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162052\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162053\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028983\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028985\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028984\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028989\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028990\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028992\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028987\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028994\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=related_link\">",
"      Docetaxel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14120?source=related_link\">",
"      Docetaxel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12534="Limited joint mobility in diabetes mellitus";
var content_f12_15_12534=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Limited joint mobility in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12534/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12534/contributors\">",
"     Lesley D Hordon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12534/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12534/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12534/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12534/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12534/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/15/12534/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited joint mobility is common in patients with diabetes mellitus. It is characterized by limitation of joint movement that is most marked in the small joints of the hands [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thickening and waxiness of the skin are also common, particularly on the dorsal surface of the fingers, but these skin changes may occur in the absence of limited joint mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of limited joint mobility in diabetes mellitus has ranged from 8 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. This variability depends largely upon the population studied and the way in which joint mobility is measured. Care must also be taken to avoid confusion with other diabetic hand problems such as Dupuytren's contracture, flexor tenosynovitis, trigger finger, and reflex sympathetic dystrophy, which may coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=see_link\">",
"     \"Musculoskeletal complications in diabetes mellitus\"",
"    </a>",
"    .) Limited joint mobility also occurs in the absence of diabetes, with prevalence figures varying between 12 and 25 percent in nondiabetic subjects of three studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited joint mobility occurs in both type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. The risk increases with increasing hemoglobin A1C values [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/8\">",
"     8",
"    </a>",
"    ] and the duration of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ], although it can occur early in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence also increases with age and cigarette smoking in both diabetics and nondiabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/7,11\">",
"     7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two cross-sectional studies have investigated the prevalence of limited joint mobility in patients with diabetes over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children and adolescents between the ages of 7 to 18 years, the prevalence of limited joint mobility fell significantly from 31 percent to 7 percent, between 1976 to 1978 and 1988 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults with type 1 diabetes (mean age 27 years) the prevalence decreased from 43 percent to 23 percent between 1981 and 1982 and 2002 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In both studies, limited joint mobility was associated with longer duration of diabetes, but the severity of limited joint mobility declined over time. The authors of both studies postulated that improvements in long-term glycemic control over the last 20 to 30 years caused the reduction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deposition of abnormal collagen in connective tissue around joints is thought to lead to the stiffening and associated skin changes of limited joint mobility. Enzymatic and nonenzymatic glycosylation of collagen, abnormal crosslinking of collagen (which results in resistance to degradation), and increased collagen hydration may all contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/2,14-16\">",
"     2,14-16",
"    </a>",
"    ]. In addition, microangiopathy and neuropathy may contribute to contractures via fibrosis and disuse.",
"   </p>",
"   <p>",
"    Early glycosylation of skin collagen can be decreased by improved glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. However, the long-term, cumulative damage due to the binding of advanced glycosylation end products to collagen is probably irreversible. There has been one case report of resolution of limited joint mobility in a patient with longstanding diabetes after pancreatic transplantation and consequent immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/17\">",
"     17",
"    </a>",
"    ]. In this particular case, resolution was possibly related to treatment with corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited joint mobility is painless. Patients come to the clinician when stiffness and contractures lead to decreased grip strength, declining ability to do fine movements, and difficulties with hand function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination of the hands may show contractures of the proximal interphalangeal and metacarpophalangeal joints. The distal interphalangeal joints may also be involved, followed less commonly by wrists, elbows, shoulders, knees, and the axial skeleton.",
"   </p>",
"   <p>",
"    Coexisting stenosing flexor tenosynovitis (trigger finger) and Dupuytren's contracture may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/19\">",
"     19",
"    </a>",
"    ]. The findings in the hands may be confused with Dupuytren's contracture in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=see_link\">",
"     \"Dupuytren's contracture\"",
"    </a>",
"    .) There are two features that may be helpful in distinguishing between them:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited joint mobility involves all four fingers, whereas Dupuytren's contracture more commonly affects just the fourth and fifth digits.",
"     </li>",
"     <li>",
"      The taut fibrotic bands characteristic of Dupuytren's contracture are not often present in limited joint mobility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two simple tests are used for diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"prayer sign\" tests the ability to flatten the hands together as in prayer, facilitating recognition of contractures in the metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints (",
"      <a class=\"graphic graphic_picture graphicRef70769 \" href=\"UTD.htm?29/12/29888\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The \"table top test\" assesses the ability to flatten the palm against the surface of a table, facilitating recognition of contractures in the metacarpophalangeal joints (",
"      <a class=\"graphic graphic_picture graphicRef77892 \" href=\"UTD.htm?4/36/4687\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Goniometers can also be used to measure flexion and extension of finger and other joints, and are of particular value in research studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although imaging studies are not typically used to diagnose limited joint mobility, thickening of the flexor tendon sheaths has been noted on ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/20\">",
"     20",
"    </a>",
"    ]. MRI findings include thickening and edema of the flexor digitorum tendons and enhancement of the tendon sheaths, without involvement of the extensor tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ASSOCIATIONS WITH OTHER DIABETIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited joint mobility is strongly associated with the duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. There are conflicting data on the possible association of limited joint mobility with glycemic control and with microvascular and other complications of diabetes mellitus. Differences in patient populations, the definition of limited joint mobility, and the methods of diagnosis contribute to this variability. In addition, there may be differences between longitudinal studies, where diabetes control is assessed over a period of time, and cross sectional studies that depend on much fewer measurements of A1C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether diabetic control and limited joint mobility are correlated is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Although biochemical theories and some clinical evidence suggest that glycemic control may prevent or minimize limited joint mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/14,16\">",
"     14,16",
"    </a>",
"    ], other reports have shown no association [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/6,9,23\">",
"     6,9,23",
"    </a>",
"    ]. A large cross sectional study of 335 adolescents and adults with type 1 diabetes found no evidence for an association between glycemic control and limited joint mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/22\">",
"     22",
"    </a>",
"    ]. Methodological differences, as discussed above, may be responsible for some of the variation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Microvascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are reports supporting the association of the disorder with retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/4,10,24\">",
"     4,10,24",
"    </a>",
"    ] and nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/4,10,25\">",
"     4,10,25",
"    </a>",
"    ], findings that have not been confirmed in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/9,23\">",
"     9,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gender may play a role in determining which diabetic complications are present in association with limited joint mobility. In a cross sectional study in patients with type 1 diabetes, men with limited joint mobility were more likely to have proteinuria, retinopathy, and hypertension than men with normal joint motion; women with limited joint mobility did not have increased rates of these problems [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One prospective study evaluated 44 patients with and without limited joint mobility who did not have retinopathy and nephropathy at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/23\">",
"     23",
"    </a>",
"    ]. After 10 years, similar numbers of patients in both groups developed retinopathy and microalbuminuria.",
"   </p>",
"   <p>",
"    However, a larger prospective study that followed 479 children from diagnosis of type 1 diabetes over a median 10.9 years showed that 35 percent developed limited joint mobility at a median age of 13 years and duration of diabetes of 5.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/25\">",
"     25",
"    </a>",
"    ]. The risk of developing limited joint mobility was related to puberty and higher A1C levels. The development of limited joint mobility was also associated with an increased risk of microalbuminuria, independent of glycemic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Foot ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors predispose to foot ulcers in diabetic patients, including neuropathy, high foot pressures, peripheral vascular disease, and trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .) Limited joint mobility in the metatarsophalangeal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/26\">",
"     26",
"    </a>",
"    ] and the subtalar joints [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] can contribute to high foot pressures, contributing to plantar ulceration. More than one-third of adolescents may have limited mobility of the first metatarsophalangeal joint and approximately 20 percent have limited subtalar motion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited joint mobility is difficult to treat. Glycemic control should be optimized, although this may be of theoretical rather than practical benefit. In addition, physiotherapy with passive palmar stretching and occupational therapy may improve function. Stretching of the toes and subtalar joint has been suggested to reduce the risk of foot ulceration, but this is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking should be discouraged. Drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , which inhibits collagen crosslinking, aminoguanidine, which prevents glycosylation of proteins and diminishes glycosylation-related crosslinking, and the aldose reductase inhibitor sorbinil may eventually prove to be beneficial; however, they are not recommended at present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13000?source=see_link\">",
"     \"Aldose reductase inhibitors in the prevention of diabetic complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injection of the palmar tendon sheath with corticosteroids was found in one study to improve the contractures of limited joint mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12534/abstract/30\">",
"     30",
"    </a>",
"    ]. This report, however, was difficult to assess because of the frequent coexistence of trigger finger and limited joint mobility. The procedure was painful.",
"   </p>",
"   <p>",
"    In contrast to the general irreversibility of limited joint mobility, other diabetic hand problems such as Dupuytren's contracture, flexor tenosynovitis, and reflex sympathetic dystrophy that can coexist with it are potentially treatable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=see_link\">",
"     \"Musculoskeletal complications in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited joint mobility is a painless stiffening of the joints seen particularly in the hands in people with both type 1 and type 2 diabetes. The deposition of abnormal collagen in connective tissue around joints is thought to lead to the stiffening and associated skin changes of limited joint mobility. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence increases with duration of diabetes and there is some evidence linking limited joint mobility to long-term glycemic control. The prevalence in young people with type 1 diabetes is declining, perhaps reflecting better long-term glycemic control in recent years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful clinical evaluation should be performed to exclude treatable diabetic hand problems such as carpal tunnel, flexor tenosynovitis, and Dupuytren's contractures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While good glycemic control and cessation of smoking are not proven to have an impact on limited joint mobility, it is logical to recommend these measures both in view of the pathogenesis of limited joint mobility and for the other benefits to the patient. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physiotherapy with passive palmar stretching and occupational therapy may improve function. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/1\">",
"      Jelinek JE. The skin in diabetes. Diabet Med 1993; 10:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/2\">",
"      Kapoor A, Sibbitt WL Jr. Contractures in diabetes mellitus: the syndrome of limited joint mobility. Semin Arthritis Rheum 1989; 18:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/3\">",
"      Seibold JR. Digital sclerosis in children with insulin-dependent diabetes mellitus. Arthritis Rheum 1982; 25:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/4\">",
"      Arkkila PE, Kantola IM, Viikari JS. Limited joint mobility in type 1 diabetic patients: correlation to other diabetic complications. J Intern Med 1994; 236:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/5\">",
"      Ramchurn N, Mashamba C, Leitch E, et al. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. Eur J Intern Med 2009; 20:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/6\">",
"      Clarke CF, Piesowicz AT, Spathis GS. Limited joint mobility in children and adolescents with insulin dependent diabetes mellitus. Ann Rheum Dis 1990; 49:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/7\">",
"      Eadington DW, Patrick AW, Frier BM. Association between connective tissue changes and smoking habit in type 2 diabetes and in non-diabetic humans. Diabetes Res Clin Pract 1991; 11:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/8\">",
"      Silverstein JH, Gordon G, Pollock BH, Rosenbloom AL. Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 1998; 132:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/9\">",
"      Gamstedt A, Holm-Glad J, Ohlson CG, Sundstr&ouml;m M. Hand abnormalities are strongly associated with the duration of diabetes mellitus. J Intern Med 1993; 234:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/10\">",
"      Garg SK, Chase HP, Marshall G, et al. Limited joint mobility in subjects with insulin dependent diabetes mellitus: relationship with eye and kidney complications. Arch Dis Child 1992; 67:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/11\">",
"      Schulte L, Roberts MS, Zimmerman C, et al. A quantitative assessment of limited joint mobility in patients with diabetes. Goniometric analysis of upper extremity passive range of motion. Arthritis Rheum 1993; 36:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/12\">",
"      Infante JR, Rosenbloom AL, Silverstein JH, et al. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr 2001; 138:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/13\">",
"      Lindsay JR, Kennedy L, Atkinson AB, et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. Diabetes Care 2005; 28:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/14\">",
"      Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/15\">",
"      Buckingham B, Reiser KM. Relationship between the content of lysyl oxidase-dependent cross-links in skin collagen, nonenzymatic glycosylation, and long-term complications in type I diabetes mellitus. J Clin Invest 1990; 86:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/16\">",
"      Lyons TJ, Bailie KE, Dyer DG, et al. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/17\">",
"      Hider SL, Roy DK, Augustine T, et al. Resolution of diabetic cheiroarthropathy after pancreatic transplantation. Diabetes Care 2004; 27:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/18\">",
"      Shah AK, Clatworthy MR, Watson CJ. Diabetic cheiroarthropathy following simultaneous pancreas-kidney transplantation. Transpl Int 2009; 22:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/19\">",
"      Kameyama M, Meguro S, Funae O, et al. The presence of limited joint mobility is significantly associated with multiple digit involvement by stenosing flexor tenosynovitis in diabetics. J Rheumatol 2009; 36:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/20\">",
"      Ismail AA, Dasgupta B, Tanqueray AB, Hamblin JJ. Ultrasonographic features of diabetic cheiroarthropathy. Br J Rheumatol 1996; 35:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/21\">",
"      Mihmanli I, Khanna G, Ferguson P. MRI of diabetic cheiroarthropathy. AJR Am J Roentgenol 2007; 188:W94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/22\">",
"      Frost D, Beischer W. Limited joint mobility in type 1 diabetic patients: associations with microangiopathy and subclinical macroangiopathy are different in men and women. Diabetes Care 2001; 24:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/23\">",
"      McCance DR, Crowe G, Quinn MJ, et al. Incidence of microvascular complications in type 1 diabetic subjects with limited joint mobility: a 10-year prospective study. Diabet Med 1993; 10:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/24\">",
"      Akanji AO, Bella AF, Osotimehin BO. Cheiroarthropathy and long term diabetic complications in Nigerians. Ann Rheum Dis 1990; 49:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/25\">",
"      Amin R, Bahu TK, Widmer B, et al. Longitudinal relation between limited joint mobility, height, insulin-like growth factor 1 levels, and risk of developing microalbuminuria: the Oxford Regional Prospective Study. Arch Dis Child 2005; 90:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/26\">",
"      Turner DE, Helliwell PS, Burton AK, Woodburn J. The relationship between passive range of motion and range of motion during gait and plantar pressure measurements. Diabet Med 2007; 24:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/27\">",
"      Delbridge L, Perry P, Marr S, et al. Limited joint mobility in the diabetic foot: relationship to neuropathic ulceration. Diabet Med 1988; 5:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/28\">",
"      Fernando DJ, Masson EA, Veves A, Boulton AJ. Relationship of limited joint mobility to abnormal foot pressures and diabetic foot ulceration. Diabetes Care 1991; 14:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/29\">",
"      Duffin AC, Donaghue KC, Potter M, et al. Limited joint mobility in the hands and feet of adolescents with Type 1 diabetes mellitus. Diabet Med 1999; 16:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12534/abstract/30\">",
"      Sibbitt WL Jr, Eaton RP. Corticosteroid responsive tenosynovitis is a common pathway for limited joint mobility in the diabetic hand. J Rheumatol 1997; 24:931.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1802 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12534=[""].join("\n");
var outline_f12_15_12534=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ASSOCIATIONS WITH OTHER DIABETIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Microvascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Foot ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1802|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/12/29888\" title=\"picture 1\">",
"      Prayer sign in diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/36/4687\" title=\"picture 2\">",
"      Table top test in diabetes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13000?source=related_link\">",
"      Aldose reductase inhibitors in the prevention of diabetic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=related_link\">",
"      Dupuytren's contracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12535="Screening for hereditary hemochromatosis";
var content_f12_15_12535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for hereditary hemochromatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12535/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12535/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12535/contributors\">",
"     Bruce R Bacon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12535/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12535/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12535/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12535/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/15/12535/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis (HH), also called genetic hemochromatosis, is an inherited disorder in which mutations in the HFE gene or other genes (eg, hemojuvelin, hepcidin, ferroportin, transferrin receptor-2) (",
"    <a class=\"graphic graphic_table graphicRef56329 \" href=\"UTD.htm?16/60/17356\">",
"     table 1",
"    </a>",
"    ) cause increased intestinal iron absorption, resulting in systemic iron overload and end-organ damage, especially in the liver, heart, and endocrine organs.",
"   </p>",
"   <p>",
"    While HH in a newly diagnosed patient may be far advanced, screening of first-degree family members or normal populations may allow diagnosis at an early stage, before irreversible organ damage has occurred. There is general agreement that first-degree relatives of patients with hereditary hemochromatosis (HH) should be screened for the disease. In contrast, population screening for HH remains a topic of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Both of these approaches will be reviewed here.",
"   </p>",
"   <p>",
"    The genetics, pathophysiology, clinical manifestations, diagnosis, and treatment of HH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FAMILY SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to justify screening for HH in first-degree family members of a proband with homozygous HH, accurate information concerning disease penetrance and progression in those so identified is critical. However, only limited information is available.",
"   </p>",
"   <p>",
"    In an informative, observational study, the incidence of iron overload (ie, serum ferritin &gt;325",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    in males or &gt;125",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    in females) and disease-related conditions (ie, cirrhosis, hepatic fibrosis, elevated aminotransferase values in the absence of any identifiable cause other than iron overload, or radiographically confirmed hemochromatotic arthropathy of the metacarpal- phalangeal joints) was determined in 214 homozygous C282Y relatives of 291 homozygous probands [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/4\">",
"     4",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of having at least one disease-related condition was 79 percent for clinically affected male probands (ie, those presenting with signs and symptoms of HH), 29 percent in male probands discovered because of an increased transferrin saturation, and 38 percent in male first-degree relatives found to have homozygous HH.",
"     </li>",
"     <li>",
"      Of the 61 homozygous male first-degree relatives younger than age 40 at the time of screening, 20 percent had no evidence of iron overload, 54 percent had iron overload only, and 26 percent had iron overload plus at least one disease-related condition. For the 52 relatives &gt;40 at the time of screening, these incidences were 10, 38, and 52 percent, respectively.",
"     </li>",
"     <li>",
"      Of the 58 homozygous female first-degree relatives younger than 50 at the time of screening, 47 percent had no evidence of iron overload, 48 percent had iron overload only, and 5 percent had iron overload plus at least one disease-related condition. For the 43 female relatives &gt;50, these incidences were 12, 72, and 16 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study revealed that a substantial number of homozygous relatives of patients with HH, more commonly men than women, had conditions related to HH that were not yet detected clinically. This suggests that screening of first-degree relatives is likely to uncover a high percentage of affected individuals, many of whom do not yet have irreversible disease and would be expected to respond favorably to therapeutic phlebotomy.",
"   </p>",
"   <p>",
"    In study of 735 first-degree family members (FDFMs) of 224 patients with clinically diagnosed HH and homozygosity for C282Y, severity of iron overload in the proband significantly predicted serum ferritin levels in the FDFMs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/5\">",
"     5",
"    </a>",
"    ]. Other determinants of disease severity in the FDFMs included C282Y homozygosity, compound heterozygosity, age at testing, supplemental iron intake, and body mass.",
"   </p>",
"   <p>",
"    The issue of disease penetrance was evaluated in a prospective cohort study of 31,192 Australian subjects of northern European ancestry, in whom the incidence of C282Y homozygosity was 0.68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/6\">",
"     6",
"    </a>",
"    ]. During 12 years of follow-up, 28 percent of male homozygotes and only 1.2 percent of female homozygotes satisfied criteria for documented iron overload plus evidence of iron-overload-related disease (ie, one or more of the following: cirrhosis, liver fibrosis, hepatocellular carcinoma, elevated aminotransferase levels, physician-diagnosed symptomatic hemochromatosis, arthropathy of the second and third metacarpophalangeal joints). Male C282Y homozygotes with a serum ferritin &ge;1000",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    were more likely to report fatigue, use of arthritis medicine, and a history of liver disease than were men who had the wild-type HFE gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Methodology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal strategies for screening first-degree relatives of patients with hemochromatosis have not been established. A cost-effectiveness analysis compared the following strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum iron studies (ie, serum iron, transferrin or total iron binding capacity, transferrin saturation, serum ferritin) in first-degree relatives.",
"     </li>",
"     <li>",
"      Genetic testing of the proband. If the proband is homozygous for C282Y, genetic testing is done to determine whether the spouse is also a carrier for a mutation. If the spouse is heterozygous for C282Y, the children undergo genetic testing.",
"     </li>",
"     <li>",
"      Genetic testing of the proband. If the proband is homozygous for the C282Y HFE mutation, relatives undergo genetic testing.",
"     </li>",
"     <li>",
"      Direct genetic testing of relatives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most cost-effective strategy for screening one child was HFE testing of the proband ($508 per life-year saved). The most cost-effective strategy for screening two or more children was HFE testing of the proband followed by testing of the spouse (incremental cost-effectiveness ratio $3665 per life-year saved). All screening strategies were cost-effective compared with no screening in siblings. Strategies using HFE testing were less costly than those using serum iron studies. The above strategies are reasonable provided that the proband is an HFE homozygote.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For first-degree relatives of probands with HH, a fasting transferrin saturation and ferritin concentration may be an appropriate initial screening method (with confirmation by genetic testing) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, as a practical measure, we also test for mutations in the HFE gene during the same visit, since most patients do not wish to return for additional blood drawing. The optimal timing for screening family members is between the ages of 18 and 30, when hemochromatosis is usually evident from iron tests, but serious organ damage (eg, cirrhosis, cardiac iron overload) has not yet occurred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POPULATION SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The notion of population screening is attractive because of the relatively high prevalence of HH in the population. As an example, about one in 200 North Europeans, and one in 230 Caucasians from the United States, is homozygous for the C282Y mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ]. The possibility exists that early detection and treatment would have a significant impact on morbidity and mortality if symptomatic patients are identified before cirrhosis has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/13\">",
"     13",
"    </a>",
"    ]. However, counter arguments have been raised, based on the low penetrance of this disorder (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H6#H6\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'HH genotype and clinical disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of studies, in several different populations, have provided evidence that screening with measurements of transferrin saturation is effective in identifying patients with HH.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study involved screening of 12,258 patients seeking care at the Mayo Clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/14\">",
"       14",
"      </a>",
"      ]. Eight patients, aged 38 to 71, had transferrin saturation equal to or greater than 62 percent; four were subsequently identified as having HH with elevated iron stores. The overall incidence of HH was",
"      <span class=\"nowrap\">",
"       0.33/1000",
"      </span>",
"      subjects screened.",
"     </li>",
"     <li>",
"      A higher prevalence of HH",
"      <span class=\"nowrap\">",
"       (4.5/1000)",
"      </span>",
"      was found in 16,031 ambulatory patients without a previous diagnosis of hemochromatosis who were screened by transferrin saturation and serum ferritin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Screening 3977 asymptomatic ambulatory men, 30 years and older, presenting for routine health checkups, resulted in the identification of 40 patients with elevated transferrin saturation, 8 of whom subsequently were diagnosed with HH [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/16\">",
"       16",
"      </a>",
"      ]. Seven of the cases were found among the 1974 white subjects who were screened",
"      <span class=\"nowrap\">",
"       (3.6/1000).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of cost-effectiveness concluded that screening was an effective strategy for asymptomatic men provided that the prevalence of HH was at least 3 per 1000, the probability of developing disease manifestations was greater than 40 percent, and the test cost was less than $12 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/17\">",
"     17",
"    </a>",
"    ]. The authors concluded that the cost per life per year saved was less than that considered acceptable for many common medical interventions. They recommended that practitioners consider including a serum transferrin saturation in routine screening of asymptomatic white men. Given that the current estimates of the probability of developing disease manifestations (ie, penetrance) is on the order of 5 percent or less, rather than &gt;40 percent, this cost-effectiveness estimate is no longer considered valid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other arguments against comprehensive screening are based upon the following issues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/1,19-26\">",
"     1,19-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential of discrimination by employers and life insurance companies against those detected by such screening",
"     </li>",
"     <li>",
"      Reluctance of health care carriers to pay for phlebotomy therapy for asymptomatic individuals",
"     </li>",
"     <li>",
"      Generation of anxiety in those being screened",
"     </li>",
"     <li>",
"      The observation that not all of those so identified currently suffer, or will suffer in the future, from the consequences of iron overload (ie, variable penetrance, see below)",
"     </li>",
"     <li>",
"      The lack of proof that earlier phlebotomy in the population identified via screening reduces morbidity and mortality compared with treatment after a diagnosis has been made during routine clinical care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional issue with large-scale screening is how this information will be presented to participants. In the Hemochromatosis and Iron Overload Screening (HEIRS) study, participants received their test results by mail, written in their native language [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/27\">",
"     27",
"    </a>",
"    ]. The level of understanding of test results was not sufficient for this mode of notification to stand alone, especially for non-English speaking participants as well as those with one or more test results outside of the normal range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of the HFE gene and the subsequent availability of genetic testing have provided another potential means of screening for HH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .) A listing of genetic testing laboratories is available through",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     GeneTests",
"    </a>",
"    , an NIH-funded medical genetics information resource [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost-effectiveness of genetic testing as a screening method was studied in a decision analysis in which it was estimated that it would cost $109,358 to identify one homozygote with potentially life-threatening illness among the population of healthy blood donors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/30\">",
"     30",
"    </a>",
"    ]. This cost is substantially higher than other screening modalities (such as mammography) that have been considered to be cost-effective. However, the estimate was based upon an average cost of $173 per genetic test. The model estimated that initial genetic testing would be cost-effective if the cost per test could be reduced to less than $28.",
"   </p>",
"   <p>",
"    Another study compared screening with unbound iron-binding capacity (the difference between bound and total iron), transferrin saturation, and genetic testing in 5211 voluntary blood donors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/31\">",
"     31",
"    </a>",
"    ]. The most cost-effective measure for preselecting patients for further study was the unbound iron-binding capacity; optimal thresholds were &le;28",
"    <span class=\"nowrap\">",
"     micromol/L.",
"    </span>",
"    The transferrin saturation was slightly less accurate at an optimal threshold of &ge;46 percent.",
"   </p>",
"   <p>",
"    Additional information on this subject was obtained from a study of 41,038 individuals attending a Kaiser Permanente health appraisal clinic in San Diego [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/1\">",
"     1",
"    </a>",
"    ]. All participants answered a health questionnaire concerning symptoms potentially related to HH, and received comprehensive laboratory screening as well as mutation analysis of the HFE gene. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening identified 152 individuals with the",
"      <span class=\"nowrap\">",
"       C282Y/C282Y",
"      </span>",
"      genotype, 45 of whom had been previously diagnosed with HH. Of importance, only 1 of the 152 homozygotes identified fit criteria usually applied to the clinical diagnosis of HH.",
"     </li>",
"     <li>",
"      The age distribution of homozygotes and compound heterozygotes did not differ significantly from that of controls: there was no measurable loss of individuals homozygous for C282Y from the population during aging.",
"     </li>",
"     <li>",
"      When frequent blood donors were excluded from the analysis, transferrin saturation was &gt;50 percent in 76 and 41 percent of homozygous men and women, respectively, and serum ferritin levels were &gt;250",
"      <span class=\"nowrap\">",
"       microg/L",
"      </span>",
"      in 77 and 56 percent, respectively.",
"     </li>",
"     <li>",
"      No symptoms (eg, fatigue, joint symptoms, skin darkening, impotence, diabetes, arrhythmias) were significantly more common in subjects with hemochromatosis genotypes than in controls, with the exception of loss of body hair [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Homozygotes were 2.1 times (95% CI 1.1-4.0) more likely to report \"liver problems\" than controls and 2.1 times more likely to have serum aspartate aminotransferase concentrations &gt;40",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      (95% CI 0.9-5.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that it would be more expensive to screen for HH than previously thought, due to the low penetrance of this disorder, estimated from this study to be less than 1 percent (ie, only 1 of the 152 homozygotes identified in this study fit criteria usually applied to the clinical diagnosis of HH).",
"   </p>",
"   <p>",
"    The yield of severe liver disease was similarly low in the Hemochromatosis and Iron Overload Screening (HEIRS) Study, which screened 101,168 primary care participants for iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/33\">",
"     33",
"    </a>",
"    ]. Of the 333 C282Y homozygotes detected, 75 had been previously diagnosed. Of the 302 C282Y homozygotes who underwent additional testing, 16 and 12 percent had increased levels of ALT and AST, respectively, compared with 11 and 8 percent, respectively, in controls. Of the 11 centrally-reviewed liver biopsies, all showed increased liver iron concentrations, but only two had stage 3 or 4 fibrosis.",
"   </p>",
"   <p>",
"    A different conclusion was reached in an Australian study that compared symptoms, laboratory findings, and the results of liver biopsy in two groups of patients. Group 1 consisted of 401 homozygous C282Y subjects detected via screening of relatives with proven C282Y-associated HH. Group 2 consisted of 271 homozygous C282Y subjects detected by primary care physicians primarily on routine health checks. Results for the two groups of subjects were quite similar, as follows (all comparisons are group 1 versus group 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated serum ALT levels &mdash; 15 versus 28 percent",
"     </li>",
"     <li>",
"      At least one disease-related condition present (ie, arthropathy, diabetes, hepatomegaly, hypogonadism, arrhythmia) &mdash; 17 versus 27 percent",
"     </li>",
"     <li>",
"      Grade 3 to 4 iron present on liver biopsy &mdash; 69 versus 82 percent",
"     </li>",
"     <li>",
"      Stage 2 or 3 fibrosis on liver biopsy &mdash; 15 versus 18 percent",
"     </li>",
"     <li>",
"      Cirrhosis on liver biopsy &mdash; 5 versus 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that screening for HH in the primary care setting and family screening revealed comparable levels of hepatic fibrosis and cirrhosis in C282Y homozygotes. Of importance, all those undergoing periodic phlebotomy had a reduction in the degree of hepatic fibrosis and all subjects with cirrhosis were asymptomatic, suggesting that screening for HH is effective in detecting patients with significant but reversible disease, and should not be confined to patients with symptomatic liver disease or relatives of probands with HH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1998 consensus statement from the Centers for Disease Control and Prevention and the National Human Genome Research Unit did not recommend population-based genetic screening for HH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/35\">",
"     35",
"    </a>",
"    ]. This recommendation was based upon uncertainty regarding the prevalence and penetrance of HFE mutations and the optimal care of asymptomatic individuals who have this mutation. The panel also cited possible stigmatization and discrimination among those with a positive screening test as a factor in their decision.",
"   </p>",
"   <p>",
"    Two systematic reviews of the available literature from 1966 through 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/36\">",
"     36",
"    </a>",
"    ] or 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/26\">",
"     26",
"    </a>",
"    ] concerning all of the above-noted issues concluded that the available evidence does not demonstrate that benefits outweigh risks and costs of screening for hemochromatosis in the primary care setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based in part on the first of these reviews [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/36\">",
"       36",
"      </a>",
"      ], an American College of Physicians Clinical Practice Guideline concluded that there was insufficient evidence to recommend for or against such screening in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Based in part on the second of these reviews [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/26\">",
"       26",
"      </a>",
"      ], the United States Preventive Services Task Force recommended against the use of routine genetic screening for HH in the asymptomatic general population [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from the Australian study cited above, if confirmed by others, may cause us to reevaluate these recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12535/abstract/34,38\">",
"     34,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"       \"Patient information: Hemochromatosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"       \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale",
"    <strong>",
"     for",
"    </strong>",
"    screening family members or populations for hereditary hemochromatosis (HH) is that this may allow diagnosis at an early stage, before irreversible organ damage has occurred.",
"   </p>",
"   <p>",
"    On the other hand, the rationale",
"    <strong>",
"     against",
"    </strong>",
"    screening is based upon the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects identified as having HH may never demonstrate clinically significant iron overload (ie, low or variable penetrance).",
"     </li>",
"     <li>",
"      There is the potential of discrimination by employers and life insurance companies against those detected by such screening.",
"     </li>",
"     <li>",
"      There may be a reluctance of health care carriers to pay for treatment (ie, phlebotomy) of asymptomatic individuals.",
"     </li>",
"     <li>",
"      There is a lack of proof that earlier phlebotomy in the population identified via screening reduces morbidity and mortality compared with treatment after a diagnosis has been made during routine clinical care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Family screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although based on limited information, in a family containing at least one member with symptomatic HH, we recommend that a fasting transferrin saturation and ferritin concentration, along with testing for mutations in the HFE gene, be obtained in all first-degree relatives when they are between the ages of 18 and 30, as opposed to not testing such relatives, or as opposed to testing such relatives at a later age (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Family screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Population screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on available information, we suggest that screening of asymptomatic populations for HH not be performed (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Population screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H948434\">",
"    <span class=\"h2\">",
"     Use of iron studies to detect iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of iron studies to screen for iron overload is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Cutoff levels for screening purposes'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/1\">",
"      Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G--&gt; A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/2\">",
"      McDonnell SM, Parrish RG. Hereditary hemochromatosis and its elusive natural history. Arch Intern Med 2003; 163:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/3\">",
"      Dubois S, Kowdley KV. The importance of screening for hemochromatosis. Arch Intern Med 2003; 163:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/4\">",
"      Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/5\">",
"      Jacobs EM, Hendriks JC, van Deursen CT, et al. Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study. J Hepatol 2009; 50:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/6\">",
"      Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/7\">",
"      El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000; 132:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/8\">",
"      Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/9\">",
"      Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008; 149:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/10\">",
"      Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/11\">",
"      Pietrangelo A. Hereditary hemochromatosis--a new look at an old disease. N Engl J Med 2004; 350:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/12\">",
"      Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/13\">",
"      Niederau C, Niederau CM, Lange S, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998; 128:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/14\">",
"      Balan V, Baldus W, Fairbanks V, et al. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology 1994; 107:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/15\">",
"      Phatak PD, Sham RL, Raubertas RF, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998; 129:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/16\">",
"      Baer DM, Simons JL, Staples RL, et al. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995; 98:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/17\">",
"      Phatak PD, Guzman G, Woll JE, et al. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994; 154:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/18\">",
"      Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111:3373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/19\">",
"      Alper JS, Geller LN, Barash CI, et al. Genetic discrimination and screening for hemochromatosis. J Public Health Policy 1994; 15:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/20\">",
"      Jackson HA, Carter K, Darke C, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001; 114:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/21\">",
"      Mainous AG 3rd, Gill JM, Pearson WS. Should we screen for hemochromatosis? An examination of evidence of downstream effects on morbidity and mortality. Arch Intern Med 2002; 162:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/22\">",
"      Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/23\">",
"      Shaheen NJ, Lawrence LB, Bacon BR, et al. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. Am J Gastroenterol 2003; 98:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/24\">",
"      Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001; 5:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/25\">",
"      U.S. Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006; 145:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/26\">",
"      Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006; 145:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/27\">",
"      Harrison HF, Harrison BW, Walker AP, et al. Screening for hemochromatosis and iron overload: satisfaction with results notification and understanding of mailed results in unaffected participants of the HEIRS study. Genet Test 2008; 12:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/28\">",
"      Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341:718.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/ (Accessed on July 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/30\">",
"      Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999; 94:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/31\">",
"      Adams PC, Kertesz AE, McLaren CE, et al. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000; 31:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/32\">",
"      Waalen J, Felitti V, Gelbart T, et al. Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc 2002; 77:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/33\">",
"      Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006; 4:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/34\">",
"      Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/35\">",
"      Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998; 280:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/36\">",
"      Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005; 143:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/37\">",
"      Qaseem A, Aronson M, Fitterman N, et al. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 143:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12535/abstract/38\">",
"      Bacon BR. Screening for hemochromatosis. Arch Intern Med 2006; 166:269.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7070 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-A161942C46-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12535=[""].join("\n");
var outline_f12_15_12535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FAMILY SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Methodology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POPULATION SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Family screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Population screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H948434\">",
"      Use of iron studies to detect iron overload",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7070\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7070|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/60/17356\" title=\"table 1\">",
"      Variants hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=related_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=related_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12536="Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access";
var content_f12_15_12536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Mark Little, MRCPI, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Karen Woo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12536/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12536/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/15/12536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of hemodialysis arteriovenous vascular access, which may be the end result of a number of complications, is a major problem in maintenance hemodialysis. The most common complication is thrombosis of the fistula or graft, which is discussed elsewhere, but other problems such as seroma, extremity swelling,",
"    <span class=\"nowrap\">",
"     aneurysm/pseudoaneurysm",
"    </span>",
"    formation, neuropathy, extremity ischemia, heart failure, and infection can also occur. These complications are reviewed here.",
"   </p>",
"   <p>",
"    Thrombotic complications of chronic hemodialysis arteriovenous vascular access are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=see_link\">",
"     \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12721967\">",
"    <span class=\"h1\">",
"     UPPER VERSUS LOWER EXTREMITY ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of chronic hemodialysis access in the lower extremity mirror those of the upper extremity for autogenous and prosthetic access. However, in the literature, complications are almost exclusively reviewed with respect to patients with upper extremity arteriovenous access, predominantly due to the infrequency of lower extremity access, which is reserved for patients who have exhausted their upper extremity sites [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Important differences pertaining to the development of complications between the lower versus upper extremity include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lower extremities are more often affected by peripheral occlusive disease. Although symptomatic steal may affect the upper and lower extremity equally, the need for upper extremity amputation is uncommon, whereas lower extremity tissue loss and major amputation as a complication of lower extremity hemodialysis access is not infrequent.",
"     </li>",
"     <li>",
"      The proximity of the lower extremity access to the lower gastrointestinal tract likely predisposes these sites to a higher incidence of infectious complications. Body habitus also affects the ability to maintain an adequate state of basic hygiene in the region of the access.",
"     </li>",
"     <li>",
"      Cannulation may be more difficult in lower extremity access and predisposes to hematoma and aneurysm formation when &ldquo;easier&rdquo; sites are repeatedly accessed.",
"     </li>",
"     <li>",
"      Compartment syndrome can occur after femoral vein transposition [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In retrospective reviews of lower extremity hemodialysis access, non-thrombotic complications occur in about half of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Representative complication rates are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aneurysmal degeneration requiring revision (6.5 percent)",
"     </li>",
"     <li>",
"      Severe ipsilateral leg ischemia (15.5 percent)",
"     </li>",
"     <li>",
"      Lower extremity amputation (6.5 percent)",
"     </li>",
"     <li>",
"      Heart failure (4 percent)",
"     </li>",
"     <li>",
"      Graft infection (18 to 20 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12721642\">",
"    <span class=\"h1\">",
"     SEROMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration of plasma across a prosthetic graft made of polytetrafluoroethylene (PTFE), also known as \"weeping syndrome\" occurs occasionally and forms a pocket of serous fluid that can become firm and gelatinous over time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/5\">",
"     5",
"    </a>",
"    ]. Seromas typically form in the arterial limb of the graft where intraluminal pressure is higher, although the same process can occur in the venous limb if there is significant central venous obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/6\">",
"     6",
"    </a>",
"    ]. Seromas usually form slowly, beginning within 30 days after implantation of the graft; however, a more acute presentation mimicking a hematoma has been reported. Graft revision may become necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12722594\">",
"    <span class=\"h1\">",
"     EXTREMITY SWELLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremity swelling is most commonly due to central vein stenosis but can also be due to venous valvular incompetence, which results in chronic elevation of the venous pressure in the extremity. The resulting venous hypertension can lead to skin discoloration, access dysfunction and potentially ischemic changes of the skin. Although mild to moderate extremity swelling is common initially following access surgery, it usually subsides. If the problem persists beyond two weeks, an underlying problem will be found in about 25 percent of cases. Venous duplex ultrasound is a sensitive test to demonstrate dilated central veins and possibly reversal of flow, but in some cases, extremity venography may be needed. Treatment is aimed at correcting the underlying vascular problem, either via percutaneous venous angioplasty or direct surgical approach, which may consist of venous patch angioplasty or graft revision [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the creation of an arteriovenous fistula, we perform a screening duplex examination of the proximal veins in patients who have a history of ipsilateral central venous catheter placement or those who have dilated chest wall veins for occult venous hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=see_link\">",
"     \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=see_link\">",
"      \"Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12721750\">",
"    <span class=\"h1\">",
"     ANEURYSM/PSEUDOANEURYSM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysms/pseudoaneurysms",
"    of hemodialysis vascular access are at risk for complications including rupture, infection, bleeding, and erosion of the overlying skin. Aneurysms and pseudoaneurysms are abnormally dilated (&gt;150 percent the normal diameter) focal regions of a blood vessel. A true aneurysm contains all the layers of the vessel wall. The etiology of true aneurysms in arteriovenous access is unclear. Proposed etiologies include increased venous pressure due to a central venous stenosis, repeated punctures at the same site, and immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. A pseudoaneurysm represents a focal disruption of the vessel wall with a collection of blood outside the vessel wall that is contained by fibrous tissue. Pseudoaneurysms usually result from repeated cannulation in the same area of the fistula and are a particular problem with arteriovenous grafts, occurring with increasing frequency over time as the graft material deteriorates. Cannulation through a pseudoaneurysm should be avoided. Pseudoaneurysms can be prevented by rotating the sites of needle insertion.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Aneurysms/pseudoaneurysms",
"    </span>",
"    are at risk for complications including rupture, infection, and erosion of the overlying skin. Any of the following changes in the overlying skin require urgent evaluation to prevent rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor eschar formation after needle removal",
"     </li>",
"     <li>",
"      Spontaneous bleeding from access sites",
"     </li>",
"     <li>",
"      Rapid expansion in pseudoaneurysm size",
"     </li>",
"     <li>",
"      Exposed graft",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines and The 2006 Canadian Society of Nephrology hemodialysis guidelines suggest that primary arteriovenous fistulas should be revised when an aneurysm develops if [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The skin overlying the fistula is compromised",
"     </li>",
"     <li>",
"      There is a risk of fistula rupture",
"     </li>",
"     <li>",
"      Available puncture sites are limited",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arteriovenous prosthetic grafts with degenerative changes may also require repair to prevent rupture. If a pseudoaneurysm is small (&lt;5 mm), it may be possible to occlude the pseudoaneurysm using compression under ultrasonic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/13\">",
"     13",
"    </a>",
"    ], with or without the local injection of thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Grafts with more severe degenerative changes, such as those listed below, will require",
"    <span class=\"nowrap\">",
"     revision/repair",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pseudoaneurysm that is symptomatic",
"     </li>",
"     <li>",
"      Pseudoaneurysm that is twice the diameter of the graft (ie, &gt;4 cm in diameter)",
"     </li>",
"     <li>",
"      Pseudoaneurysm that threatens the viability of the overlying skin, regardless of diameter",
"     </li>",
"     <li>",
"      Evidence of infection",
"     </li>",
"     <li>",
"      Pseudoaneurysm that is expanding",
"     </li>",
"     <li>",
"      Large or multiple pseudoaneurysms that limit the number of cannulation sites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12722019\">",
"    <span class=\"h1\">",
"     NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Median nerve dysfunction in long-term dialysis patients is most often due to local amyloid deposition, leading to carpal tunnel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2643?source=see_link\">",
"     \"Uremic mononeuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vascular access also may contribute to this problem in some cases via compression of the median nerve (due to the extravasation of blood or fluid) or via ischemic injury by a vascular steal effect (ischemic monomelic neuropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12722337\">",
"     'Extremity ischemia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Nerve ischemia/infarct'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12722337\">",
"    <span class=\"h1\">",
"     EXTREMITY ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with significant arterial stenosis distal to the fistula, placement of an arteriovenous access can lead to reduced perfusion of the more distal extremity as a result of shunting (\"steal\") of arterial blood flow into the fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/20\">",
"     20",
"    </a>",
"    ]. Symptomatic steal occurs in up to 20 percent of patients receiving an upper extremity access [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], with severe manifestations requiring intervention in 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/23\">",
"     23",
"    </a>",
"    ]. Factors that contribute to the development of steal include failure of adequate collateral flow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excessive fistula blood flow (large fistula). Steal typically manifests a median of two days after the placement of a prosthetic arteriovenous graft, whereas steal associated with an arteriovenous fistula is delayed as the blood flow through the access progressively increases as the fistula matures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute ischemic symptoms characterized by an absent pulse or a cold extremity warrant immediate surgical correction (often ligation of the fistula or graft) to prevent the development of permanent injury. These severe complications may be more common among patients with diabetes and those of advanced age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. More commonly, less severe symptoms and signs, such as paresthesias and a sense of coolness with retained pulses, usually improve over a period of weeks with the development of collateral blood flow. Careful, frequent clinical evaluation and an alert nursing staff are required in this setting. Symptoms often worsen during dialysis sessions.",
"   </p>",
"   <p>",
"    Symptomatic steal from an internal mammary artery coronary artery bypass from an ipsilateral upper extremity dialysis access has been reported to cause myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. When planning vascular access placement in a patient with an internal mammary bypass, it is best to use the upper extremity contralateral to the internal mammary graft. Likewise, when contemplating use of the left internal mammary for coronary bypass in a dialysis patient with a left upper-extremity shunt, it may be useful to angiographically document the absence of reversal of flow in the internal mammary artery during diastole before using that artery as a coronary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination alone may not be accurate in identifying vascular steal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, among patients presenting with symptoms of extremity ischemia, there should be a low threshold to obtain noninvasive vascular evaluation using duplex ultrasound, which may identify the presence of arterial stenosis, and physiologic tests such as digital waveforms and pressures with and without fistula compression, which are sensitive for a diagnosis of steal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. If noninvasive studies are unrevealing and ischemic symptoms persist, arteriography of the extremity may identify an anatomic problem [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous catheter-based intervention may be an option in patients with ischemic symptoms found to have proximal inflow arterial stenosis or progressive arterial occlusive disease in the extremity distal to the fistula origin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]. One prospective study evaluated the effectiveness of percutaneous transluminal balloon angioplasty or surgical intervention in patients with an arteriogram demonstrating a distal native arterial stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/27\">",
"     27",
"    </a>",
"    ]. Arterial stenosis was found in 10 of 12 patients with steal, 8 of whom underwent successful angioplasty. At a mean follow-up of eight months, all patients treated with angioplasty were successfully using their access.",
"   </p>",
"   <p>",
"    If surgical intervention is required and preservation of the arteriovenous fistula is a high priority, the procedure of choice is Distal Revascularization with Interval Ligation (DRIL procedure) (",
"    <a class=\"graphic graphic_figure graphicRef76970 \" href=\"UTD.htm?11/30/11748\">",
"     figure 1",
"    </a>",
"    ). In this procedure, the artery is ligated distal to the anastomosis to prevent retrograde flow and persistent steal, and perfusion to the hand is restored with a distal bypass procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/12,32-36\">",
"     12,32-36",
"    </a>",
"    ]. The ligation and bypass procedures can be performed at a single surgery; staged procedures are rarely needed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Other surgical interventions that avoid having distal perfusion dependent upon the bypass graft include the Revision Using Distal Inflow (RUDI) and the Minimally Invasive Limited Ligation Endoluminal-assisted Revision (MILLER) procedures (",
"    <a class=\"graphic graphic_figure graphicRef76970 \" href=\"UTD.htm?11/30/11748\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12722176\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular access-related cardiac decompensation is a rare complication, even in patients with underlying cardiac dysfunction. Patients with an arteriovenous fistula do not have higher rates of heart failure than patients using prosthetic grafts or indwelling catheters for dialysis, but may have an increase in preexisting left ventricular hypertrophy after creation of the fistula. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37063?source=see_link\">",
"     \"Heart failure and hemodialysis arteriovenous fistulae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection accounts for approximately 20 percent of vascular access loss. The vascular access is the source of the majority of bacteremia in hemodialysis patients. Staphylococcus aureus and, less commonly, Staphylococcus epidermidis are the predominant pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. Bacteremia frequently occurs during cannulation without actual fistula infection.",
"   </p>",
"   <p>",
"    Risk factors for arteriovenous vascular access infection include pseudoaneurysms, hematomas (often due to inappropriate graft cannulation), severe pruritus and scratching over needle sites, the use of hemodialysis fistulas as a route of access for injection drug abuse, and manipulation of the access during secondary surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Tunneled catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although antibiotic prophylaxis is indicated at the time of the surgical creation or revision of an arteriovenous vascular access (",
"    <a class=\"graphic graphic_table graphicRef87206 \" href=\"UTD.htm?34/1/34844\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63103 \" href=\"UTD.htm?33/9/33950\">",
"     table 2",
"    </a>",
"    ), antibiotic administration with routine use of the access during hemodialysis has been unsuccessful in preventing fistula infection and may be dangerous. The use of nasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    to eradicate nasal carriage of S. aureus can reduce the incidence of Staphylococcus aureus bacteremia in hemodialysis patients. However, this approach is complicated by the development of mupirocin resistance with chronic use [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, nasal mupirocin is best reserved for patients with repeated infection and nasal Staphylococcus aureus carriage, and in the setting of epidemic infections in the dialysis unit.",
"   </p>",
"   <p>",
"    An underappreciated infective complication is the clinically silent infection of a clotted hemodialysis graft that is no longer being used. One study addressed this issue by performing indium scans in dialysis patients with nonfunctional grafts, 20 with fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis but without localizing signs, and 21 asymptomatic control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/47\">",
"     47",
"    </a>",
"    ]. Indium scans showed uptake in the graft in all patients with clinical infection and in 15 of the controls. Graft removal revealed infected clot in all patients, including 13 of the 15 controls with positive scans. The most commonly cultured organisms were Staphylococcus aureus or Staphylococcus epidermidis. Graft infection, even if clinically silent, must be entertained in the dialysis patient presenting systemic symptoms and signs of infection and positive localization on a nuclear study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection occurring in native arteriovenous fistulas can usually be treated with intravenous antibiotics and, if necessary, surgical drainage. Since arteriovenous fistulae are rarely the primary source of the infection in the absence of a collection of pus, bacteremia is assumed to be a consequence of endocarditis. Thus, the 2006",
"    <span class=\"nowrap\">",
"     NKF/Dialysis",
"    </span>",
"    Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    guidelines recommend six weeks of antibiotic therapy for access-mediated bacteremia in a patient with an arteriovenous fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/10\">",
"     10",
"    </a>",
"    ]. With septic emboli, surgical excision of the fistula should be performed.",
"   </p>",
"   <p>",
"    In contrast, infected arteriovenous grafts generally require surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/50\">",
"     50",
"    </a>",
"    ]. Depending upon the extent of the infection, treatment involves incision and drainage with excision of the affected graft material (if localized), or complete removal of the graft. As an example, minimal infection that develops in an area of exposed graft can be often treated with intravenous antimicrobials, excision of the exposed graft segment and rerouting the graft through uninvolved tissue. Any skin overlying the graft that is compromised is excised [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/51\">",
"     51",
"    </a>",
"    ]. The graft that remains must have adequate coverage. The",
"    <span class=\"nowrap\">",
"     NKF/Dialysis",
"    </span>",
"    Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    guidelines recommend three weeks of antibiotic therapy for access-mediated bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/11\">",
"     11",
"    </a>",
"    ]. The graft should be evaluated frequently to ensure that the infection has been adequately controlled.",
"   </p>",
"   <p>",
"    Persistent fever or bacteremia following complete removal of an infected arteriovenous access should prompt the search for another source (eg, endocarditis, osteomyelitis) or metastatic infection. Metastatic infection is much more common with cuffed hemodialysis catheters but can occur with arteriovenous fistulas or grafts. Overall patient outcome appears to be much worse when an arteriovenous access is the source of metastatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12536/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=see_link&amp;anchor=H18#H18\">",
"     \"Complications of Staphylococcus aureus bacteremia\", section on 'Metastatic seeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12721515\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of an arteriovenous vascular access is a major problem in maintenance hemodialysis and may be the end result of a number of complications. The most common complication of arteriovenous vascular access is thrombosis, which is discussed elsewhere, but other problems such as seroma, extremity swelling,",
"      <span class=\"nowrap\">",
"       aneurysm/pseudoaneurysm,",
"      </span>",
"      neuropathy, extremity ischemia, heart failure, and infection can also occur. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complications of chronic hemodialysis access in the lower extremity mirror those of the upper extremity for autogenous and prosthetic arteriovenous access. However, predominantly due to the infrequency of lower extremity access, complications are almost exclusively reviewed in the literature with respect to patients with upper extremity arteriovenous access. Some important differences between upper and lower extremity sites impact the risk of vascular access complications. (See",
"      <a class=\"local\" href=\"#H12721967\">",
"       'Upper versus lower extremity access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrafiltration of plasma across prosthetic grafts can form a pocket of serous fluid that can become firm and gelatinous over time. Seromas typically form in the arterial limb of the graft but can form in the venous limb if venous pressure is elevated. (See",
"      <a class=\"local\" href=\"#H12721642\">",
"       'Seroma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe limb edema and the sequelae of venous hypertension are most commonly due to central vein stenosis but can also result from venous valvular incompetence. If swelling persists beyond two weeks following the creation of a vascular access, venous duplex ultrasound should be obtained and is a sensitive test to demonstrate dilated veins and reversal of flow. Treatment is aimed at correcting the underlying vascular problem. (See",
"      <a class=\"local\" href=\"#H12722594\">",
"       'Extremity swelling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Aneurysms/pseudoaneurysms",
"      </span>",
"      of hemodialysis vascular access are at risk for complications including rupture, infection, bleeding, and erosion of the overlying skin. Aneurysm formation in arteriovenous access may be related to increased venous pressure due to central venous stenosis, repeated puncture at the same site, or immunosuppression. Pseudoaneurysms usually result from repeated cannulation of the same region of the arteriovenous vascular access and can be prevented by rotating needle insertion sites. If a pseudoaneurysm is small (&lt;5 mm), it may be possible to occlude it using direct compression under ultrasonic guidance. Severely degenerated arteriovenous access should be repaired to lower the risk of rupture. Indications include large",
"      <span class=\"nowrap\">",
"       aneurysms/pseudoaneurysms",
"      </span>",
"      (&ge;4 cm in diameter), those with skin changes overlying the access, spontaneous bleeding, and those in which the number of cannulation sites has become limited. (See",
"      <a class=\"local\" href=\"#H12721750\">",
"       'Aneurysm/pseudoaneurysm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropathy in long-term dialysis patients is most often due to local amyloid deposition causing median nerve dysfunction and carpal tunnel syndrome. The vascular access also may contribute to this problem in some cases via nerve compression due to the extravasation of blood or fluid, or as a result of ischemic nerve injury from a vascular steal effect. (See",
"      <a class=\"local\" href=\"#H12722019\">",
"       'Neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Placement of an arteriovenous access reduces perfusion of the extremity and may lead to extremity ischemia. Symptoms of steal often worsen during dialysis sessions. Factors that contribute to the development of steal include failure of adequate collateral flow",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      excessive fistula blood flow. Steal typically manifests a couple of days after placement of an arteriovenous graft, whereas steal associated with an arteriovenous fistula develops over a longer timeframe as the fistula matures and flow through the access progressively increases. Imaging the arterial circulation of the extremity will identify any native arterial stenoses, and percutaneous intervention (angioplasty) may be effective at correcting the lesion(s). For multiple stenoses or arterial occlusion, fistula revision, fistula ligation, or extremity revascularization may be needed. (See",
"      <a class=\"local\" href=\"#H12722337\">",
"       'Extremity ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection accounts for about 20 percent of hemodialysis vascular access loss. Risk factors include pseudoaneurysm, hematoma, scratching at needle sites due to pruritus, the use of hemodialysis access as a route for injection drug abuse, and manipulation of the access during secondary surgical procedures. Infection occurring in autogenous arteriovenous fistulas can usually be treated with intravenous antibiotics and, when needed, surgical drainage. Infection associated with prosthetic graft material requires removal of a portion or all of the graft. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1123892295\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Stephen Smith, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/1\">",
"      Taylor SM, Eaves GL, Weatherford DA, et al. Results and complications of arteriovenous access dialysis grafts in the lower extremity: a five year review. Am Surg 1996; 62:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/2\">",
"      Korzets A, Ori Y, Baytner S, et al. The femoral artery-femoral vein polytetrafluoroethylene graft: a 14-year retrospective study. Nephrol Dial Transplant 1998; 13:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/3\">",
"      Vogel KM, Martino MA, O'Brien SP, Kerstein MD. Complications of lower extremity arteriovenous grafts in patients with end-stage renal disease. South Med J 2000; 93:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/4\">",
"      Carsten CG 3rd. Lower extremity arteriovenous hemodialysis access: an important adjunct in select patients. Semin Vasc Surg 2011; 24:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/5\">",
"      Fivez F, Van Hee R, Beelaerts W, Schoofs E. Pseudotumor formation in polytetrafluoroethylene-dialysis fistulae. Am J Kidney Dis 1986; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/6\">",
"      Eid A, Lyass S. Acute perigraft seroma simulating anastomotic bleeding of a PTFE graft applied as an arteriovenous shunt for hemodialysis. Ann Vasc Surg 1996; 10:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/7\">",
"      Chen JC, Kamal DM, Jastrzebski J, Taylor DC. Venovenostomy for outflow venous obstruction in patients with upper extremity autogenous hemodialysis arteriovenous access. Ann Vasc Surg 2005; 19:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/8\">",
"      Woo K, Cook PR, Garg J, et al. Midterm results of a novel technique to salvage autogenous dialysis access in aneurysmal arteriovenous fistulas. J Vasc Surg 2010; 51:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/9\">",
"      Pasklinsky G, Meisner RJ, Labropoulos N, et al. Management of true aneurysms of hemodialysis access fistulas. J Vasc Surg 2011; 53:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/10\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/11\">",
"      NKF-DOQI Clinical Practice Guidelines for Vascular Access. V. Management of complications: Optimal approaches for treating complications. Am J Kidney Dis 2001; 37(Suppl 1):S163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/12\">",
"      Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/13\">",
"      Witz M, Werner M, Bernheim J, et al. Ultrasound-guided compression repair of pseudoaneurysms complicating a forearm dialysis arteriovenous fistula. Nephrol Dial Transplant 2000; 15:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/14\">",
"      Clark TW, Abraham RJ. Thrombin injection for treatment of brachial artery pseudoaneurysm at the site of a hemodialysis fistula: report of two patients. Cardiovasc Intervent Radiol 2000; 23:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/15\">",
"      Palder SB, Kirkman RL, Whittemore AD, et al. Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985; 202:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/16\">",
"      Miles AM. Vascular steal syndrome and ischaemic monomelic neuropathy: two variants of upper limb ischaemia after haemodialysis vascular access surgery. Nephrol Dial Transplant 1999; 14:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/17\">",
"      Gilbert MS, Robinson A, Baez A, et al. Carpal tunnel syndrome in patients who are receiving long-term renal hemodialysis. J Bone Joint Surg Am 1988; 70:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/18\">",
"      Reyal Y, Robinson C, Salama A, Levy JB. Neurological complications from brachial arteriovenous fistulae. Nephrol Dial Transplant 2004; 19:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/19\">",
"      Thermann F, Kornhuber M. Ischemic monomelic neuropathy: a rare but important complication after hemodialysis access placement--a review. J Vasc Access 2011; 12:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/20\">",
"      Leon C, Asif A. Arteriovenous access and hand pain: the distal hypoperfusion ischemic syndrome. Clin J Am Soc Nephrol 2007; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/21\">",
"      Papasavas PK, Reifsnyder T, Birdas TJ, et al. Prediction of arteriovenous access steal syndrome utilizing digital pressure measurements. Vasc Endovascular Surg 2003; 37:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/22\">",
"      Tordoir JH, Dammers R, van der Sande FM. Upper extremity ischemia and hemodialysis vascular access. Eur J Vasc Endovasc Surg 2004; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/23\">",
"      Lazarides MK, Staramos DN, Kopadis G, et al. Onset of arterial 'steal' following proximal angioaccess: immediate and delayed types. Nephrol Dial Transplant 2003; 18:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/24\">",
"      Crowley SD, Butterly DW, Peter RH, Schwab SJ. Coronary steal from a left internal mammary artery coronary bypass graft by a left upper extremity arteriovenous hemodialysis fistula. Am J Kidney Dis 2002; 40:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/25\">",
"      Gaudino M, Serricchio M, Luciani N, et al. Risks of using internal thoracic artery grafts in patients in chronic hemodialysis via upper extremity arteriovenous fistula. Circulation 2003; 107:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/26\">",
"      Kato H, Ikawa S, Hayashi A, Yokoyama K. Internal mammary artery steal in a dialysis patient. Ann Thorac Surg 2003; 75:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/27\">",
"      Asif A, Leon C, Merrill D, et al. Arterial steal syndrome: a modest proposal for an old paradigm. Am J Kidney Dis 2006; 48:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/28\">",
"      Yilmaz C, Ozcan K, Erkan N. Dialysis access-associated steal syndrome presenting as bidirectional flow at duplex Doppler ultrasound. AJR Am J Roentgenol 2009; 193:W568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/29\">",
"      Moghazy KM. Value of color Doppler sonography in the assessment of hemodialysis access dysfunction. Saudi J Kidney Dis Transpl 2009; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/30\">",
"      Malik J, Slavikova M, Maskova J. Dialysis access-associated steal syndrome: the role of ultrasonography. J Nephrol 2003; 16:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/31\">",
"      Tordoir JH, Van Der Sande FM, De Haan MW. Current topics on vascular access for hemodialysis. Minerva Urol Nefrol 2004; 56:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/32\">",
"      Wixon CL, Hughes JD, Mills JL. Understanding strategies for the treatment of ischemic steal syndrome after hemodialysis access. J Am Coll Surg 2000; 191:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/33\">",
"      Berman SS, Gentile AT, Glickman MH, et al. Distal revascularization-interval ligation for limb salvage and maintenance of dialysis access in ischemic steal syndrome. J Vasc Surg 1997; 26:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/34\">",
"      Knox RC, Berman SS, Hughes JD, et al. Distal revascularization-interval ligation: a durable and effective treatment for ischemic steal syndrome after hemodialysis access. J Vasc Surg 2002; 36:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/35\">",
"      Diehl L, Johansen K, Watson J. Operative management of distal ischemia complicating upper extremity dialysis access. Am J Surg 2003; 186:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/36\">",
"      Schanzer H, Eisenberg D. Management of steal syndrome resulting from dialysis access. Semin Vasc Surg 2004; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/37\">",
"      Goel N, Miller GA, Jotwani MC, et al. Minimally Invasive Limited Ligation Endoluminal-assisted Revision (MILLER) for treatment of dialysis access-associated steal syndrome. Kidney Int 2006; 70:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/38\">",
"      Miller GA, Goel N, Friedman A, et al. The MILLER banding procedure is an effective method for treating dialysis-associated steal syndrome. Kidney Int 2010; 77:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/39\">",
"      Fan PY, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol 1992; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/40\">",
"      Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993; 21:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/41\">",
"      Munda R, First MR, Alexander JW, et al. Polytetrafluoroethylene graft survival in hemodialysis. JAMA 1983; 249:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/42\">",
"      Bhat DJ, Tellis VA, Kohlberg WI, et al. Management of sepsis involving expanded polytetrafluoroethylene grafts for hemodialysis access. Surgery 1980; 87:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/43\">",
"      Albers FJ. Clinical considerations in hemodialysis access infection. Adv Ren Replace Ther 1996; 3:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients--United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/45\">",
"      Anderson JE, Chang AS, Anstadt MP. Polytetrafluoroethylene hemoaccess site infections. ASAIO J 2000; 46:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/46\">",
"      Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003; 37:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/47\">",
"      Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/48\">",
"      Nassar GM, Ayus JC. Clotted arteriovenous grafts: a silent source of infection. Semin Dial 2000; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/49\">",
"      Nassar GM, Ayus JC. Infectious complications of old nonfunctioning arteriovenous grafts in renal transplant recipients: a case series. Am J Kidney Dis 2002; 40:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/50\">",
"      Bosman PJ, Blankestijn PJ, van der Graaf Y, et al. A comparison between PTFE and denatured homologous vein grafts for haemodialysis access: a prospective randomised multicentre trial. The SMASH Study Group. Study of Graft Materials in Access for Haemodialysis. Eur J Vasc Endovasc Surg 1998; 16:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/51\">",
"      McKenna PJ, Leadbetter MG. Salvage of chronically exposed Gore-Tex vascular access grafts in the hemodialysis patient. Plast Reconstr Surg 1988; 82:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12536/abstract/52\">",
"      Kovalik EC, Raymond JR, Albers FJ, et al. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection. J Am Soc Nephrol 1996; 7:2264.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1860 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-CBD0E914AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12536=[""].join("\n");
var outline_f12_15_12536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12721515\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12721967\">",
"      UPPER VERSUS LOWER EXTREMITY ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12721642\">",
"      SEROMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12722594\">",
"      EXTREMITY SWELLING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12721750\">",
"      ANEURYSM/PSEUDOANEURYSM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12722019\">",
"      NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12722337\">",
"      EXTREMITY ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12722176\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12721515\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1123892295\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1860|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/30/11748\" title=\"figure 1\">",
"      Bypass revision for brachiocephalic fistula steal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/1/34844\" title=\"table 1\">",
"      Antimicrobial prophylaxis for vascular surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/9/33950\" title=\"table 2\">",
"      Prophylaxis recommendations for vascular and IR procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37063?source=related_link\">",
"      Heart failure and hemodialysis arteriovenous fistulae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=related_link\">",
"      Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2643?source=related_link\">",
"      Uremic mononeuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12537="VF incongr incompl HH";
var content_f12_15_12537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F79091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F79091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Visual fields: Incongruous incomplete homonymous hemianopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 399px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Humphrey visual field showing a right incongruous incomplete homonymous hemianopia secondary to a left optic tract tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12537=[""].join("\n");
var outline_f12_15_12537=null;
var title_f12_15_12538="Approach to the patient with genital ulcers";
var content_f12_15_12538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with genital ulcers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12538/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12538/contributors\">",
"     Sonia N Chimienti, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12538/contributors\">",
"     Donna Felsenstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12538/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/15/12538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/15/12538/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/15/12538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital ulcers may be due to an infectious or noninfectious etiology, although most are caused by sexually transmitted infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of specific pathogens differs depending upon geographic location. The diagnosis of the cause of genital ulcers is complicated by the fact that more than one infection may coexist. In addition, the presence of genital ulcers is a risk factor for the transmission of HIV. The challenge for the clinician is to determine the cause of the genital ulcers in order to institute appropriate therapy and to decrease the risk of transmission to others.",
"   </p>",
"   <p>",
"    The approach to the patient with genital ulcers is discussed below. More detailed information regarding the individual diseases can be found on the relevant topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18837?source=see_link\">",
"     \"Laboratory monitoring of patients undergoing treatment for syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious etiologies of genital ulcers include sexually transmitted pathogens, such as [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes simplex virus (HSV)",
"     </li>",
"     <li>",
"      Treponema pallidum (the causative agent of syphilis)",
"     </li>",
"     <li>",
"      Haemophilus ducreyi (the causative agent of chancroid)",
"     </li>",
"     <li>",
"      Chlamydia trachomatis serovars L1-3 (the causative agents of lymphogranuloma venereum; LGV)",
"     </li>",
"     <li>",
"      Klebsiella granulomatis (the causative agent of Granuloma inguinale; also known as &ldquo;Donovanosis&rdquo;)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, primary infection with HIV or cytomegalovirus (CMV) can be associated with genital ulceration. Some epidemiologic studies also suggest that Epstein-Barr virus (EBV) may be sexually transmitted. Rarely, EBV can lead to genital ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H3#H3\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Transmission'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Noninfectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious etiologies include fixed drug reactions, Beh&ccedil;et&rsquo;s disease, neoplasms, and trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive evaluation of the patient with genital ulcers requires a thorough knowledge of the epidemiology of sexually transmitted pathogens in a given locale. Knowledge of the relative prevalence of various pathogens in a particular geographic area helps to inform selection of appropriate empiric therapy. (See",
"    <a class=\"local\" href=\"#H45\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, genital herpes related to HSV-1 or HSV-2 infection is reported to be the most common ulcerative sexually transmitted disease (STD) followed by syphilis; chancroid is a distant third, often in the context of small focused outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, there are approximately 320,000 doctor visits for genital herpes annually [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, in 2007 there were 11,466 cases of primary and secondary syphilis and 23 cases of chancroid reported to the Centers for Disease Control (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/7\">",
"     7",
"    </a>",
"    ]. The actual incidence of various STDs is thought to be under reported due to lack of recognition by the treating clinician or failure of a patient to seek medical care.",
"   </p>",
"   <p>",
"    LGV has been rarely reported in resource-rich countries except in the context of localized outbreaks, which have been reported in New York, Amsterdam, London, and many other urban areas in North America and Europe among men who have sex with men (MSM). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link&amp;anchor=H2#H2\">",
"     \"Lymphogranuloma venereum\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same three infections (genital herpes, syphilis, and chancroid) cause the majority of genital ulcers in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, the prevalence rates vary from country to country [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/12\">",
"     12",
"    </a>",
"    ]. The following studies serve as illustrative examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a South African study of 1160 men, HSV was the most frequent cause of genital ulcers (29 percent) followed by H. ducreyi (25 percent) and T. pallidum (16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a Rwandan study of 1025 patients with genital ulcers, H. ducreyi was the most common cause in men, while T. pallidum was most frequently identified in women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chancroid remains particularly common in South Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/13\">",
"     13",
"    </a>",
"    ], although the prevalence in Botswana declined significantly from 25 percent to 1 percent over a nine-year period in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/14\">",
"     14",
"    </a>",
"    ]. This decline of chancroid cases was accompanied by a rise in the proportion of cases secondary to HSV-2 infection. An increase in the proportion of cases secondary to HSV-2 infection has also been reported in Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/15\">",
"     15",
"    </a>",
"    ]. One potential explanation for this observation is the prevalent use of antibiotics for empiric therapy of genital ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LGV can also be found in areas of East and West Africa, India, parts of Southeast Asia, and the Caribbean. Granuloma inguinale, an uncommon infection caused by Klebsiella granulomatis, has been recognized in parts of India, Papua New Guinea, the Caribbean, South America, and Australia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient who presents with genital ulcers should have a comprehensive history and physical examination for pertinent symptoms and signs, as discussed below. The classic presentations of the various etiologic agents are summarized in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef81735 \" href=\"UTD.htm?21/54/22381\">",
"     table 1",
"    </a>",
"    ). However, the overlapping nature of signs and symptoms in persons with genital ulcers makes use of clinical criteria alone for diagnosis unreliable. In addition, infection with more than one pathogen can occur, since coinfections are not uncommon. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Limitations of a clinical diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sexual history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough sexual history should be obtained from any patient who presents with a genital ulcer. This should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gender of the sexual contacts (men, women, or both)",
"     </li>",
"     <li>",
"      Number of sexual contacts within the past month and past six months",
"     </li>",
"     <li>",
"      Sites of sexual contact (oral, genital, rectal)",
"     </li>",
"     <li>",
"      Use of barrier protection (consistent or inconsistent)",
"     </li>",
"     <li>",
"      Geographic location of the partner (eg, another country versus locally). The geographic location of a sexual contact may give clues to the etiologic agent or the risk of antibiotic resistance (eg, drug-resistant chancroid).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be queried about risk-taking behaviors and the time of onset of risk relative to the onset of signs and symptoms, which may give potential clues about the incubation period. The medical history should also address the use of drugs (eg, methamphetamine)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heavy alcohol use, which are associated with an increase in high-risk behaviors. The patient should also be asked about any past history of other STDs and prior HIV testing.",
"   </p>",
"   <p>",
"    For noninfectious etiologies, a history of recurrent oral and genital lesions and uveitis may suggest Beh&ccedil;et&rsquo;s disease, while genital blisters and ulcerations that are associated with a particular medication may suggest fixed drug reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations associated with genital ulcers often do not help to differentiate the etiological agent, although certain clinical features may be helpful, such as any history of recurrence that may be suggestive of HSV.",
"   </p>",
"   <p>",
"    Although a history of recurrent ulcers would be consistent with HSV or Beh&ccedil;et's disease, the practitioner should never be dissuaded from considering the possibility that the current lesion being evaluated has a different etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Painful versus painless",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much emphasis is often placed on the history of whether or not a lesion is painless or painful. Painful ulcers tend to be more typical of HSV and chancroid, while ulcers associated with syphilis, LGV, and granuloma inguinale are usually painless.",
"   </p>",
"   <p>",
"    However, a clinical diagnosis made solely on this distinction may be misleading. The clinical manifestations of primary genital HSV infection are highly variable. The initial presentation can be severe with painful genital ulcers, dysuria, fever, tender local inguinal lymphadenopathy, and headache. In other patients, however, the infection is mild, subclinical, or entirely asymptomatic.",
"   </p>",
"   <p>",
"    Furthermore, herpetic ulcers can sometimes manifest as a sensation of pruritus rather than pain. In the latter case, a female patient who complains of pruritis may be misdiagnosed with a vaginal yeast infection. In contrast, syphilitic ulcers, which are classically painless, may also become secondarily infected and become painful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dysuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complaint of dysuria may be due to the anatomic location of a genital ulcer. As an example, painful urination may be the chief complaint in a female with ulcerative labial or urethral lesions or in a male with an ulcer at the urethral meatus or on the glans. On the other hand, dysuria may suggest a diagnosis of urethritis (eg, Chlamydia urethritis).",
"   </p>",
"   <p>",
"    Dysuria in a sexually active adolescent female may suggest either a urinary tract infection or a sexually transmitted infection, so both should be sought. Urinary retention would be strongly suggestive of complicated HSV infection with the development of sacral radiculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Constitutional symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constitutional symptoms can be significant in primary clinical infection with HSV, secondary syphilis, and LGV.",
"   </p>",
"   <p>",
"    Primary clinical infection due to HSV is highly variable in its presentation. Patients may present with systemic symptoms, such as fever, malaise, and myalgias. Central nervous system involvement, such as aseptic meningitis, can be suggested by headache, photophobia, and stiff neck. In contrast, in other patients, constitutional symptoms may be absent and the only complaints may be related to the anatomic location of the genital ulcers.",
"   </p>",
"   <p>",
"    Fever, headache and malaise may also occur in the secondary stage of LGV and syphilis. Although the primary syphilitic chancre has usually resolved by the time the secondary manifestations become apparent, the two stages can sometimes overlap.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Recurrent episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of recurrent ulcers would suggest HSV infection. However, if diagnostic testing does not support this diagnosis, a history of recurrent ulcers may also suggest less common noninfectious etiologies, such as Beh&ccedil;et's disease or fixed drug eruption. However, the fact that a patient has had herpetic outbreaks in the past should never dissuade the practitioner from considering another etiology for the ulcer under evaluation as the patient may have acquired a new and different infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should carefully evaluate the patient for characteristics of the ulcer and any associated lymphadenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Multiple versus single ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, infection due to HSV or H. ducreyi (chancroid) presents as multiple ulcers, whereas syphilis usually presents as a single lesion (",
"    <a class=\"graphic graphic_picture graphicRef57637 \" href=\"UTD.htm?0/27/435\">",
"     picture 1",
"    </a>",
"    ). However, making a diagnosis based on the number of genital lesions on examination can lead to misdiagnosis. For example, genital herpes can occasionally present as a single ulcer or a fissure in the genital area. Likewise, multiple syphilitic chancres may be misdiagnosed as HSV [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpetic lesions begin as one or more grouped vesicles on an erythematous base (",
"      <a class=\"graphic graphic_picture graphicRef58485 \" href=\"UTD.htm?15/36/15940\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81531 \" href=\"UTD.htm?42/30/43490\">",
"       picture 3",
"      </a>",
"      ). These vesicles subsequently open resulting in shallow ulcerations. In areas under the foreskin or around the labia and rectum, vesicles often break prior to being noticed.",
"     </li>",
"     <li>",
"      The ulcers associated with chancroid begin as papules that go on to ulcerate (",
"      <a class=\"graphic graphic_picture graphicRef60163 \" href=\"UTD.htm?22/45/23253\">",
"       picture 4",
"      </a>",
"      ). The ulcers are characteristically deep and ragged with a purulent, yellow-gray base, and an undermined, violaceous border.",
"     </li>",
"     <li>",
"      The syphilitic chancre is classically a single, indurated, well-circumscribed painless ulcer (",
"      <a class=\"graphic graphic_picture graphicRef57637 \" href=\"UTD.htm?0/27/435\">",
"       picture 1",
"      </a>",
"      ). It can, however, be soft, nonindurated, irregular, and occasionally painful.",
"     </li>",
"     <li>",
"      LGV often begins as a single papule or a shallow ulcer (",
"      <a class=\"graphic graphic_picture graphicRef81656 \" href=\"UTD.htm?36/45/37585\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef67866 \" href=\"UTD.htm?30/60/31681\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Granuloma inguinale can present as one or more nodular lesions that ulcerate. The ulcers, which slowly enlarge, are often friable and have raised, rolled margins. &ldquo;Kissing&rdquo; lesions may occur from autoinoculation on adjacent skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inguinal lymphadenopathy is commonly seen with most genital ulcer-causing infections involving the genital tract. The lymph nodes are often tender in patients with HSV, chancroid, and LGV. Rubbery, non-tender nodes are often seen in late primary syphilis. Matting or suppuration of the lymph nodes or the development of a painful \"buboe\" may occur with chancroid or LGV. Lymphadenopathy, however, is less common with granuloma inguinale, though nodular lesions may appear as pseudobuboes.",
"   </p>",
"   <p>",
"    Significant concomitant inguinal, cervical,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    axillary lymphadenopathy may raise the concern for concomitant HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is also important to assess whether the patient may have other findings to suggest concomitant STDs, such as urethral or cervical discharge (eg, gonorrhea, chlamydia), thrush (eg, HIV infection), or hepatomegaly (eg, hepatitis C or hepatitis B).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF A CLINICAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the history and physical examination may give important clues to the diagnosis, it is important for clinicians to be aware that the appearance of genital ulcers can vary and overlap. Thus, determining the etiology of a genital ulcer based upon a classic sign may lead to a mistaken diagnosis and inappropriate treatment, emphasizing the need for diagnostic testing, when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/8,10,17,18\">",
"     8,10,17,18",
"    </a>",
"    ]. However, empiric therapy should be offered while awaiting the laboratory results. (See",
"    <a class=\"local\" href=\"#H45\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, infection with each of these organisms is not mutually exclusive, as coinfection with multiple organisms can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/10\">",
"     10",
"    </a>",
"    ]. In an HIV-infected patient, the CD4 count must also be considered since immunodeficiency is associated with atypical clinical presentations (eg, multiple chancres in syphilis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of the physical examination alone for diagnosing primary syphilis, chancroid, and genital herpes were assessed in a report of 220 men in whom a single microbiologic diagnosis was established [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/18\">",
"     18",
"    </a>",
"    ]. The study was performed during an 18-month period when an outbreak of chancroid had been observed. Diagnostic testing included darkfield microscopy and rapid plasma reagin testing (RPR) for syphilis and cultures for H. ducreyi and HSV. Clinical evaluation included the number of lesions, ulcer depth, and associated pain and lymphadenopathy. The study demonstrated that the observation of any single classic sign of HSV, chancroid, or syphilis was an insensitive tool for diagnosis. In contrast, when a constellation of three clinical signs was present, the diagnosis was more specific.",
"   </p>",
"   <p>",
"    In the United States, chancroid is particularly difficult to diagnose on clinical grounds alone because most clinicians are unfamiliar with this infection since it is relatively uncommon. In addition, suspected cases are difficult to confirm because specialized assays and culture media are required [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Furthermore, some clinical providers may not consider this infection in their differential diagnosis, which may lead to inappropriate empiric therapy while awaiting diagnostic confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a study in a primary health clinic in Nairobi demonstrated a sensitivity of 91 percent for the diagnosis of chancroid attributed to a high clinical index of suspicion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in this study the specificity was only 24 percent; thus, unnecessary treatment was given to many patients, again emphasizing the importance of diagnostic testing and follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     General diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with genital ulcers should have a diagnostic evaluation for HSV and syphilis. Although repeat HSV testing may not be necessary in a patient with prior laboratory-confirmed genital HSV and with clinical manifestations consistent with recurrent disease, other etiologies should be ruled out.",
"   </p>",
"   <p>",
"    Laboratory tests at the initial clinic visit should include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral culture of the base of the ulcer for possible HSV; if a vesicle is present, vesicular fluid is preferred because of its higher diagnostic yield.",
"     </li>",
"     <li>",
"      Direct fluorescent antibody testing (DFA) performed on a scraping of the base of an ulcer can also be performed in lieu of viral culture (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Testing for herpes simplex virus'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      HSV PCR testing is commercially available and may be used in place of either HSV viral culture or DFA.",
"     </li>",
"     <li>",
"      Serologic screening for syphilis with a nontreponemal test (eg, Rapid Plasma Reagin; RPR), or treponemal test.",
"     </li>",
"     <li>",
"      Darkfield examination of the lesion can be performed if available. The limitations of diagnostic testing for HSV and syphilis are discussed below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether patients are also evaluated for chancroid, LGV, or granuloma inguinale will depend on the prevalence of these conditions in the geographic location of STD acquisition, risk profile of the person's sexual contacts, travel history of the patient and their sexual contacts, and local prevalence rates of these other causative agents. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with genital ulcers should also undergo screening for other STDs, including HIV, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H54\">",
"     'Other sexually transmitted diseases'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Limitations of diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available diagnostic tests for HSV, syphilis, and chancroid have significant limitations. In most clinical settings, there are no reliable point-of-care diagnostic tests. Furthermore, some of the assays have low sensitivity (eg, viral culture for HSV, and RPR during primary syphilis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/16\">",
"     16",
"    </a>",
"    ]. Sensitive assays, such as real-time HSV polymerase chain reaction (RT-PCR) assays, are more costly to perform and are often unavailable in emergency rooms, STD clinics, and resource-limited settings. Detailed discussions regarding the diagnosis of syphilis and genital HSV are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More detailed information regarding specimen collection and available testing assays is found below; further details on the sensitivity and specificity of the various assays are discussed within the individual disease topics. A summary of these diagnostic tests is provided (",
"    <a class=\"graphic graphic_table graphicRef77961 \" href=\"UTD.htm?26/15/26875\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Testing for herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HSV can be made by viral culture, polymerase chain reaction (PCR), direct fluorescent antibody (DFA), or Tzanck preparation. The most commonly performed test for suspected HSV is viral culture, although the overall sensitivity of this method is only approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, the sensitivities of viral culture and other tests, such as DFA, are significantly influenced by the duration of the lesion. Vesicular lesions generally have higher yield than ulcerative lesions for both viral culture (isolated in 70 versus 32 percent, respectively) and DFA (identification in 87 versus 30 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/25\">",
"     25",
"    </a>",
"    ]. DFA and PCR tests are generally more sensitive than culture, but cost considerations generally limit the availability of these assays in developing countries and in many STD clinics in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of suspected HSV, laboratory diagnosis is recommended not only for confirmation of etiology, but also for prognostication, since HSV recurrences are more common with HSV-2 rather than HSV-1 infection. HSV-1 can be differentiated from HSV-2 with all testing modalities, except for Tzanck prep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, wet lesions have a higher viral yield than dry or crusted ulcers. Thus, if a vesicle is present, the lesion should be unroofed and a sample of the fluid, along with scrapings from the ulcer base, should be sent for culture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/26\">",
"     26",
"    </a>",
"    ]. Specimens for culture should be directly placed into viral culture media and rapidly transported to the laboratory; results are generally available within a few days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Direct fluorescent antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Samples for DFA are obtained by scraping the base of an unroofed vesicle or an ulcer with a swab or the edge of a blade, which is preferable as this will increase the yield of obtaining infected cells from the base of the lesion. The specimen contents should be carefully spread over the center of a glass slide. The slide is air dried, fixed, and sent to the laboratory for testing using a monoclonal antibody. Positive results may be obtained in less than 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR assays can improve detection of HSV even when the patient presents more than five days after symptom onset. The laboratory turnaround time for PCR is significantly shorter than for viral culture (several hours compared with one or more days) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H24#H24\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Tzanck prep",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the diagnostic tests mentioned above are not available, cytopathological evidence of a herpes group virus using a Tzanck smear may be used as a diagnostic adjunct. Material is obtained by scraping the base of an ulcer with a surgical blade and then thinly smearing the material onto a slide. After the appropriate staining technique is performed, the slide is inspected for the appearance of multinucleated giant cells consistent with a herpetic infection.",
"   </p>",
"   <p>",
"    The sensitivity of this approach is less than 50 percent. Also, in contrast to the diagnostic testing described above, the Tzanck prep cannot distinguish between infection with HSV-1 or HSV-2, or from infection with other herpes viruses (eg, VZV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing has limited value in the diagnosis of a patient with ulcerative lesions and suspected HSV infection. However, type-specific serological tests may have a role in certain settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient with recurrent genital symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ulcers despite antiviral therapy, a negative HSV-1 and HSV-2 antibody test would rule out HSV as a cause of these recurrences. A noninfectious etiology should then be considered (eg, Beh&ccedil;et&rsquo;s disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serology can sometimes be helpful in documenting a primary HSV-1 or HSV-2 genital infection by demonstrating antibody seroconversion from negative to positive, but this would require that the patient return for repeat testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H24#H24\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Testing for syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of syphilis may be made indirectly via serologic testing or directly through visualization of spirochetes by darkfield microscopy or direct immunofluorescence. Direct visualization is extremely helpful for point-of-care testing; however, these direct techniques are not routinely available in most clinics or emergency rooms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontreponemal testing is commonly used for serologic screening for syphilis. Nontreponemal tests include Venereal Disease Research Laboratory (VDRL), Rapid Plasma Reagin (RPR), and Toludine Red Unheated Serum Test (TRUST).",
"   </p>",
"   <p>",
"    All nontreponemal tests are considered \"screening serologies\" and must be confirmed with specific treponemal testing since false positive nontreponemal tests can occur. Nontreponemal testing is performed initially due to its low cost. Specific treponemal tests include fluorescent treponemal antibody absorption (FTA-ABS), microhemagglutination test for antibodies to Treponema pallidum (MHA-TP), Treponema pallidum particle agglutination assay (TP-PA), and Treponema pallidum enzyme immunoassay (TP-EIA). These additional tests can also be requested at the time the patient initially presents, along with nontreponemal testing, if the suspicion for syphilis is high.",
"   </p>",
"   <p>",
"    Certain caveats pertain to laboratory testing for syphilis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A negative nontreponemal test (eg, RPR) at the time the patient presents with a lesion does not rule out the diagnosis of primary syphilis. Up to 40 percent of patients may have a negative nontreponemal test at the time of presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A patient with a recent history of treated syphilis may still have a reactive nontreponemal serology. In this situation it is important to determine if a new genital ulcer is due to reinfection with T. pallidum or another etiologic agent; a rising nontreponemal titer may indicate reinfection with T. pallidum.",
"     </li>",
"     <li>",
"      Specific treponemal testing is only helpful if the patient has never had syphilis in the past since these diagnostic tests remain persistently positive after initial infection despite curative therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complex issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Screening with specific treponemal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinical laboratories do not use nonspecific treponemal screening testing for syphilis. Instead they have adopted screening with automated enzyme immunoassays (EIAs) to detect anti-treponemal antibodies (both IgM and IgG) as the initial screening test. The rationale for this is that specific treponemal tests may become positive earlier than the nontreponemal tests.",
"   </p>",
"   <p>",
"    Patients with positive EIA results then undergo testing using standard nontreponemal assays to determine the serologic titer that will be utilized for staging of the infection and evaluation of treatment, according to specific algorithms. However, diagnostic confusion can ensue if the anti-treponemal antibody is positive and the nontreponemal test is nonreactive. This diagnostic dilemma is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Darkfield microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darkfield microscopy for T. pallidum has a specificity of 70 to 95 percent depending upon the expertise of the operator (",
"    <a class=\"graphic graphic_picture graphicRef63806 \" href=\"UTD.htm?10/49/11037\">",
"     picture 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/28\">",
"     28",
"    </a>",
"    ]. A positive darkfield requires the presence of 10(5) organisms in the specimen, which limits the sensitivity of this test. Since provider experience with the use of darkfield microscopy may be limited, recognition of the organism may be suboptimal leading to both under- and over-diagnosis of syphilis. Darkfield microscopy also has limited availability, although some newer microscopes can be converted to a darkfield microscope by changing the condenser. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Direct fluorescent antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;If darkfield microscopy is not available, clinicians may collect specimens for fluorescein-conjugated antibody staining to T. pallidum, performed by reference laboratories. Acceptable specimens include fixed smears from serous fluid expressed from lesions or lymph node aspirates. The antibody is specific for T. pallidum, thus, distinguishing between pathogenic and non-pathogenic strains in clinical specimens. Unlike darkfield microscopy, this assay may be helpful in the evaluation of oral or rectal specimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Testing for chancroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing for chancroid is limited by the availability of special culture media and by the cost of more sensitive assays, such as PCR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis is made by isolation of Haemophilus ducreyi on selective media under special conditions. While culture is the reference standard for diagnosis, it is not routinely performed in all laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/29\">",
"     29",
"    </a>",
"    ]. A wide range of sensitivities has been reported for successful culturing of H. ducreyi, the causative agent (ie, 56 to 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Gram stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Gram stained smear taken from the edge of an ulcer for evaluation for chancroid may reveal a \"railroad track\" or \"school of fish\" pattern reflecting a characteristic grouping of the Gram negative rods of Haemophilus ducreyi. In experienced hands, this method can offer helpful information at the point of service; in inexperienced hands, superficial contamination of the lesion with bacteria can lead to diagnostic confusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     PCR testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR is more sensitive than culture for the detection of H. ducreyi [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/31\">",
"     31",
"    </a>",
"    ]. In one study of 298 specimens, the sensitivity of multiplex-PCR (M-PCR) for H. ducreyi was 98 percent compared with a sensitivity of 74 percent for culture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/32\">",
"     32",
"    </a>",
"    ]. The test is not routinely available, but can be performed by specialty laboratories that have established and verified their own testing under Clinical Laboratory Improvement Amendments (CLIA) standards; such tests are generally more costly than culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Testing for lymphogranuloma venereum (LGV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of LGV is most commonly made serologically, using either microimmunofluorescence (MIF) or complement fixation (CF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active infection is indicated by either a fourfold rise in titer upon complement fixation testing or a single titer of 1:64 or higher, in a compatible clinical context.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture has low sensitivity (about 30 percent) and Chlamydia cultures are not generally available outside of referral centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11589473\">",
"    <span class=\"h3\">",
"     Nucleic acid amplification test (NAAT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid detection can be performed on a swab of a genital ulcer. Rectal lesions can also be tested by this method in laboratories that have performed validation testing as this assay is not FDA approved for this use. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Testing for granuloma inguinale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella granulomatis, the causative agent of granuloma inguinale (donovanosis), is very difficult to culture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/33\">",
"     33",
"    </a>",
"    ]. Diagnosis requires the identification of dark-staining Donovan bodies on tissue crush preparation or biopsy. Donovan bodies are rod-shaped oval organisms that can be seen in the cytoplasm of mononuclear phagocytes or histiocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Testing for multiple agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiplex polymerase chain reaction (M-PCR) alone, or combined with EIA, is a technique currently employed in research laboratories to simultaneously test for the presence of the three most common causes of genital ulcers. M-PCR is not yet available commercially in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M-PCR is sensitive and specific, with more than 90 percent sensitivity for HSV, T. pallidum, and H. ducreyi using a single swab taken from a genital ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/8,17,32\">",
"     8,17,32",
"    </a>",
"    ]. In one study, the sensitivities for HSV, H. ducreyi, and T. pallidum were 100, 98, and 91 percent, respectively, compared with 72, 74, and 81 percent, respectively, for HSV culture, H. ducreyi culture, and darkfield microscopy for T. pallidum [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/32\">",
"     32",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H35\">",
"     'Testing for chancroid'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Non-infectious etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all genital ulcers are caused by an STD, so alternative diagnoses need to be considered in those who are not at risk. A biopsy can be considered in a patient without a firm diagnosis and who is not responding to empiric therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, results of diagnostic testing are usually not available at the initial patient encounter to help guide therapy. However, early appropriate treatment of the causative agents of genital ulcers may lead to more rapid healing and relief of symptoms. Furthermore, successful eradication of these pathogens leads to a decreased risk of transmission to others. This is particularly important with genital lesions secondary to Treponema pallidum, which may spontaneously resolve without targeted therapy; however, latent infection may lead to occult transmission to sexual partners and late stage disease in the untreated patient with serious neurologic and cardiovascular sequelae over time.",
"   </p>",
"   <p>",
"    An empiric or \"syndromic\" approach is also recommended by the World Health Organization (WHO) in resource-limited settings, where diagnostic testing is often unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric treatment should be based upon the most likely diagnosis based on the clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]. For example, multiple shallow-based painful ulcers in a sexually active patient are suggestive of HSV, while a painless solitary chancre is suggestive (although not diagnostic) of syphilis. Painful ragged-edged ulcers would be suggestive of chancroid, particularly in the setting of a localized outbreak. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Knowledge of the local epidemiology of the etiologic agents that cause genital ulcers in a given geographic area can also be instructive, particularly in the setting of an outbreak. The local public health department can often be helpful in this regard since syphilis, chancroid, and lymphogranuloma venereum are reportable infections in most jurisdictions. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Empiric treatment should be considered for patients suspected of having primary syphilis at the point of care rather than waiting for diagnostic test results, if the patient is at high risk, follow-up cannot be assured, or patients are unlikely to abstain from sexual contact until diagnosis and treatment are completed.",
"   </p>",
"   <p>",
"    The disadvantage of an empiric treatment approach is the administration of inappropriate therapy. In addition, empiric treatment can interfere with further diagnostic testing, affecting the ability to confirm a diagnosis and potentially impacting contact tracing. This issue, however, may be outweighed by the risk of an untreated patient not returning for follow-up.",
"   </p>",
"   <p>",
"    Due to the limitations of the clinical diagnosis, patient follow-up is critically important, when possible, to assess the treatment response and results of diagnostic testing. At this visit, prior therapeutic decisions can be reevaluated. Clinicians should also be aware that approximately 25 percent of all patients with genital ulcers never have a specific etiologic agent identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Limitations of a clinical diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are often faced with lack of diagnostic test results at the initial patient encounter and concerns regarding patient follow-up. Early therapy of sexually transmitted infections leads to rapid relief of symptoms and a decreased risk of transmission to others. We suggest empiric therapy for patients with genital ulcers that are suggestive for HSV at presentation in the office, rather than waiting for diagnostic test results. Empiric therapy for syphilis should be considered if the patient is at high risk, or patient follow-up cannot be guaranteed. Patient follow-up should be arranged within one week to assess the clinical response to therapy and to review results of diagnostic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Suspected HSV",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Primary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected primary clinical genital HSV should receive empiric antiviral therapy, which lessens the severity and duration of symptoms compared with untreated disease. Clinical trials have demonstrated comparable efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg three times daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (250 mg three times daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (1000 mg twice daily); the last agent has the convenience of twice-daily dosing while acyclovir is less expensive than the other two medications. The usual duration of treatment is 7 to 10 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Treatment of primary HSV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of recurrent painful genital lesions in a pattern similar to past episodes, in a patient who has previously laboratory-proven genital HSV (by PCR or viral culture of lesion material), strongly suggests HSV infection. Regardless, consideration of other etiologies and appropriate diagnostic work-up should be pursued in patients at risk for acquiring a new STD. In particular, syphilis serology should be considered, especially in high-risk patients. A history of recurrent lesions without previous laboratory confirmation of HSV requires laboratory confirmation as well as testing for other possible infectious causes of genital ulcers. Recurrent painful genital lesions with repeated negative HSV testing should raise the possibility of Beh&ccedil;et's disease.",
"   </p>",
"   <p>",
"    Whether therapy will be offered for recurrent HSV will depend on several factors, including the frequency of the episodes, severity of the symptoms, and whether the patient has an uninfected sexual partner. Specific options include chronic suppression, episodic therapy, or no intervention. These management strategies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Treatment strategies for recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Suspected syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected syphilis should receive empiric therapy for T. pallidum pending diagnostic confirmation. The drug of choice is benzathine penicillin (2.4 million units), administered via the intramuscular route. Alternative agents for the penicillin allergic patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H31#H31\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Penicillin allergic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Suspected chancroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with suspected chancroid, empiric single-dose therapy should be administered with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 gram PO) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg IM). Both are effective although azithromycin is more expensive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link&amp;anchor=H15#H15\">",
"     \"Chancroid\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since some small studies have found syphilis to be a copathogen in up to 10 percent of patients with chancroid, some experts recommend concomitant treatment for primary syphilis at the time of chancroid treatment, particularly if it is likely that the patient will not return for timely follow-up. Syphilis serology should also be sent for baseline testing. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1954866\">",
"    <span class=\"h2\">",
"     Suspected granuloma inguinale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antimicrobial agents have clinical efficacy in the treatment of granuloma inguinale including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice a day),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 gram weekly),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (750 mg twice a day),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg four times a day), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (1 double-strength tablet twice a day) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/36\">",
"     36",
"    </a>",
"    ]. The CDC 2010 STD guidelines recommend doxycycline as the preferred agent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]. The duration of treatment, regardless of antibiotic selection, is a minimum of three weeks or until all lesions have completely healed. If no clinical improvement occurs within the first few days, an aminoglycoside can be added [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]. Pregnant women should be treated with erythromycin (",
"    <a class=\"graphic graphic_table graphicRef71380 \" href=\"UTD.htm?36/6/36971\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Atypical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some instances, treatment must be initiated for additional conditions because of atypical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]. Diagnostic uncertainty may be related to dual infections or atypical manifestations in the immunocompromised host (eg, multiple lesions secondary to syphilis in the HIV-infected patient). Thus, empiric therapy may require treatment for two infections pending diagnostic evaluation. In such cases, treatment for HSV and syphilis would be reasonable due to their greater prevalence, unless some other historical information suggests a different pathogen (eg, history of sexual contact with a person recently diagnosed with chancroid).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     OTHER SEXUALLY TRANSMITTED DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with genital ulcers may also be coinfected with other sexually transmitted infections, such as Chlamydia trachomatis, Neisseria gonorrhoeae, HIV, and hepatitis B and hepatitis C viruses. Many of these infections are also asymptomatic; thus screening for these infections should be part of the routine evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory tests at the initial clinic visit should include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nucleic acid amplification (NAAT) testing on a urine sample for C. trachomatis and N. gonorrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"       \"Genital Chlamydia trachomatis infections in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"       \"Genital Chlamydia trachomatis infections in men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A rapid HIV test.",
"      <br/>",
"      <br/>",
"      The specimen that can be utilized (eg, blood, plasma, serum, saliva) will depend on the specific rapid HIV test that is being utilized. Patients with a positive rapid HIV test must have confirmatory testing with an enzyme linked immunosorbent assay. Patients likely to return for follow-up may benefit from fourth generation HIV testing, which includes testing for p24 antigen, reducing the &ldquo;window period&rdquo;. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"       \"Serologic screening for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic testing for hepatitis C antibody. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Serologic testing for hepatitis C antibody can be negative in a person with acute HCV infection. If there is suspicion of acute infection (eg, right upper quadrant pain, nausea, vomiting, or recent onset of high risk behavior such as sharing of needles), an HCV RNA should also be ordered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic testing for hepatitis B surface antigen (ie, HBsAg) and surface antibody (ie, anti-HBs).",
"      <br/>",
"      <br/>",
"      If there is suspicion of acute HBV infection, then an antibody to hepatitis B core should also be requested (ie, anti-HBcore IgM antibody) in addition to the above serologies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"       \"Serologic diagnosis of hepatitis B virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic testing for syphilis as discussed above (in patients regardless of the presence or absence of a genital, oral, or anal ulcer). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling regarding partner testing and condom use is key to decreasing transmission. All patients should be advised to refrain from sexual activity while awaiting test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up evaluation is essential for all patients who have received empiric therapy to be certain a clinical response has been obtained and to complete appropriate diagnostic evaluation (ie, follow-up serology). If the patient continues to have ulcerative lesions or new onset constitutional symptoms, more testing may be required.",
"   </p>",
"   <p>",
"    A negative treponemal or nontreponemal test for syphilis does not rule out the possibility of infection in a patient with a genital ulcers; in primary syphilis, nontreponemal tests have a sensitivity as low as 60 to 87 percent depending upon the group studied [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, repeat testing is indicated in one month and three months for patients with a recent history of genital ulcers or in patients with a high clinical suspicion of syphilis who have negative screening tests initially.",
"   </p>",
"   <p>",
"    All patients diagnosed with syphilis (with a reactive nontreponemal test and a confirmatory treponemal test) should have repeat RPR testing every three months for two years. Repeat testing is important since the decline of the syphilis titer will indicate if treatment was successful or not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18837?source=see_link\">",
"     \"Laboratory monitoring of patients undergoing treatment for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If diagnostic tests for HSV and syphilis are negative, consideration should also be given to the possibility of chancroid or LGV, if these diagnoses were not strongly considered at the initial encounter.",
"   </p>",
"   <p>",
"    The follow-up patient encounter is also an opportunity to review other test results, including serologic testing for HIV and viral hepatitis. Patients who have not been vaccinated or exposed to hepatitis B virus in the past (as determined by serologic testing) should receive hepatitis B immunization. Hepatitis A immunization is also indicated for MSM and injection drug users. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     \"Hepatitis B vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of prevalence rates of the various etiologies of genital ulcers in a given area can be helpful in making a diagnosis, particularly when the clinical picture is not clear. If surveillance data are inaccurate, certain infections can be underrecognized and undertreated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/8,38\">",
"     8,38",
"    </a>",
"    ]. However, even with a thorough evaluation, up to 25 percent of patients who have genital ulcers have no laboratory-confirmed diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accurate diagnoses are also important from a public health standpoint, since treatment of sexual contacts of patients with syphilis, chancroid, and LGV is important in curbing the spread of these infections. Diagnosis and treatment of HSV not only decreases viral shedding and risk of HSV transmission, but may also decrease the risk of HIV transmission from patients who are coinfected with both HSV and HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important that patients have a confidential, easily accessible setting where they can go for STD screening and treatment. Many STD clinics offer services for no fee as part of their mission to diagnose and control the spread of infection. Introduction of even a modest clinic fee of $15 for Denver residents during a budget shortfall led to 3250 fewer STD clinic visits in 2003 (a decline of 29 percent) compared with the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/15/12538/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Partner notification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual contacts of patients with a definite diagnosis of an STD should be notified and treated. Partner notification for reportable infections such as syphilis is usually accomplished through the local public health department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genital ulcers may be due to an infectious or noninfectious etiology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, genital herpes is reported to be the most common ulcerative sexually transmitted disease followed by syphilis; chancroid is a distant third, often in the context of small focused outbreaks. In resource-limited settings, herpes simplex virus (HSV) and syphilis remain important considerations although chancroid is more commonly encountered than in resource-rich regions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient with genital ulcers should have a careful sexual and medical history. The patient should be queried about whether the ulcers are recurrent, painful, and whether constitutional symptoms have been present. The physical examination should document whether there are single or multiple lesions, whether the lesions are indurated or non-indurated, whether the lymphadenopathy is suppurative or not, and any signs of underlying HIV infection, such as oropharyngeal thrush. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the history and physical examination may give important clues to the diagnosis, it is important for clinicians to be aware that the appearance of genital ulcers can vary and overlap. Thus, supportive laboratory testing should be performed whenever possible.",
"     </li>",
"     <li>",
"      All patients with genital ulcers should have a syphilitic serology repeated one and three months after presentation. (See",
"      <a class=\"local\" href=\"#H56\">",
"       'Patient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are limitations to the clinical diagnosis, we suggest empiric therapy for patients suspected of having HSV, or those patients suspected of having primary syphilis at the point-of-care rather than waiting for diagnostic test results, if follow-up cannot be assured (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) or patients are unlikely to abstain from sexual contact until diagnosis and appropriate treatment are completed. Eradication of infection leads to prompt relief of symptoms in patients with painful ulcerative lesions and a decreased risk of transmission to others. The choice of therapy will be based on the patient's history, clinical symptoms and signs. The disadvantage of empiric therapy is the administration of inappropriate therapy. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternatively, treatment can be deferred to the second visit if the patient prefers to wait for results of diagnostic testing and follow-up is relatively certain (eg, the patient has established longitudinal care within the clinic). (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with genital ulcers may be coinfected with other sexually transmitted diseases, such as Chlamydia trachomatis, Neisseria gonorrhoeae, HIV, and hepatitis B and hepatitis C viruses. Screening for these infections should be part of the routine evaluation. (See",
"      <a class=\"local\" href=\"#H54\">",
"       'Other sexually transmitted diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A follow-up evaluation is essential for all patients who have received empiric therapy to be certain a clinical response has been obtained. Patients with a clinical diagnosis of HSV, but negative diagnostic HSV testing, should return for repeat specific treponemal testing or RPR at one and three months. If the patient continues to have ulcerative lesions or new onset constitutional symptoms, more testing may be required. (See",
"      <a class=\"local\" href=\"#H56\">",
"       'Patient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/2\">",
"      Schmid GP. Approach to the patient with genital ulcer disease. Med Clin North Am 1990; 74:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/3\">",
"      Rosen T, Brown TJ. Genital ulcers. Evaluation and treatment. Dermatol Clin 1998; 16:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/4\">",
"      Bruisten SM. Genital ulcers in women. Curr Womens Health Rep 2003; 3:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/5\">",
"      Taylor S, Drake SM, Dedicoat M, Wood MJ. Genital ulcers associated with acute Epstein-Barr virus infection. Sex Transm Infect 1998; 74:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/6\">",
"      Mart&iacute;n JM, Godoy R, Calduch L, et al. Lipsch&uuml;tz acute vulval ulcers associated with primary cytomegalovirus infection. Pediatr Dermatol 2008; 25:113.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention, Division of Sexually Transmitted Diseases. Sexually Transmitted Diseases Surveillance, Other Sexually Transmitted Diseases, 2007. www.cdc.gov/std/stats07/tables.htm (Accessed on September 30, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/8\">",
"      Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/9\">",
"      Chen CY, Ballard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000; 27:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/10\">",
"      Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/11\">",
"      Bogaerts J, Kestens L, van Dyck E, et al. Genital ulcers in a primary health clinic in Rwanda: impact of HIV infection on diagnosis and ulcer healing (1986-1992). Int J STD AIDS 1998; 9:706.",
"     </a>",
"    </li>",
"    <li>",
"     2007 National Guidelines for the management of chancroid. Clinical Effectiveness Group (British Association for Sexual Health and HIV, BASSH). www.bashh.org/guidelines (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/13\">",
"      Lai W, Chen CY, Morse SA, et al. Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa. Sex Transm Infect 2003; 79:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/14\">",
"      Paz-Bailey G, Rahman M, Chen C, et al. Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis 2005; 41:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/15\">",
"      Riedner G, Todd J, Rusizoka M, et al. Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania. Sex Transm Infect 2007; 83:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/16\">",
"      Rompalo AM, Lawlor J, Seaman P, et al. Modification of syphilitic genital ulcer manifestations by coexistent HIV infection. Sex Transm Dis 2001; 28:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/17\">",
"      Morse SA, Trees DL, Htun Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997; 175:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/18\">",
"      DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997; 25:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/19\">",
"      French P. Syphilis. BMJ 2007; 334:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/20\">",
"      Beck-Sague CM, Cordts JR, Brown K, et al. Laboratory diagnosis of sexually transmitted diseases in facilities within the United States. Results of a national survey. Sex Transm Dis 1996; 23:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/21\">",
"      Lewis DA. Chancroid: clinical manifestations, diagnosis, and management. Sex Transm Infect 2003; 79:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/22\">",
"      Ndinya-Achola JO, Kihara AN, Fisher LD, et al. Presumptive specific clinical diagnosis of genital ulcer disease (GUD) in a primary health care setting in Nairobi. Int J STD AIDS 1996; 7:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/23\">",
"      Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/24\">",
"      Groen J, Van Dijk G, Niesters HG, et al. Comparison of two enzyme-linked immunosorbent assays and one rapid immunoblot assay for detection of herpes simplex virus type 2-specific antibodies in serum. J Clin Microbiol 1998; 36:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/25\">",
"      Lafferty WE, Krofft S, Remington M, et al. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population. J Clin Microbiol 1987; 25:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/26\">",
"      Schomogyi M, Wald A, Corey L. Herpes simplex virus-2 infection. An emerging disease? Infect Dis Clin North Am 1998; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/27\">",
"      Ramaswamy M, McDonald C, Smith M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect 2004; 80:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/28\">",
"      Hart G. Syphilis tests in diagnostic and therapeutic decision making. Ann Intern Med 1986; 104:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/29\">",
"      Morse SA. Chancroid and Haemophilus ducreyi. Clin Microbiol Rev 1989; 2:137.",
"     </a>",
"    </li>",
"    <li>",
"     Totten PA, Kuypers J, Morse SA. Haemophilus ducreyi detection by PCR. In: Methods in Molecular Medicine: Sexually Transmitted Diseases Methods and Protocols, Peeling RW, Sparling PF (Eds), Humana Press, Totowa, NJ 2008. Vol 20, p.47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/31\">",
"      Chui L, Albritton W, Paster B, et al. Development of the polymerase chain reaction for diagnosis of chancroid. J Clin Microbiol 1993; 31:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/32\">",
"      Orle KA, Gates CA, Martin DH, et al. Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex virus types 1 and 2 from genital ulcers. J Clin Microbiol 1996; 34:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/33\">",
"      Carter J, Hutton S, Sriprakash KS, et al. Culture of the causative organism of donovanosis (Calymmatobacterium granulomatis) in HEp-2 cells. J Clin Microbiol 1997; 35:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/34\">",
"      Mackay IM, Harnett G, Jeoffreys N, et al. Detection and discrimination of herpes simplex viruses, Haemophilus ducreyi, Treponema pallidum, and Calymmatobacterium (Klebsiella) granulomatis from genital ulcers. Clin Infect Dis 2006; 42:1431.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO) guidelines for the Management of sexually transmitted infections. WHO/HIV_AIDS/2003.01. Geneva WHO, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/36\">",
"      O'Farrell N. Donovanosis. Sex Transm Infect 2002; 78:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/37\">",
"      Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev 1995; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/38\">",
"      Mertz KJ, Weiss JB, Webb RM, et al. An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. J Infect Dis 1998; 178:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/39\">",
"      Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/40\">",
"      Cohen MS. HIV and sexually transmitted diseases: lethal synergy. Top HIV Med 2004; 12:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/15/12538/abstract/41\">",
"      Rietmeijer CA, Alfonsi GA, Douglas JM, et al. Trends in clinic visits and diagnosed Chlamydia trachomatis and Neisseria gonorrhoeae infections after the introduction of a copayment in a sexually transmitted infection clinic. Sex Transm Dis 2005; 32:243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7592 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12538=[""].join("\n");
var outline_f12_15_12538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H59\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infectious",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Noninfectious",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sexual history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Painful versus painless",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dysuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Constitutional symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Recurrent episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Multiple versus single ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LIMITATIONS OF A CLINICAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      General diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Limitations of diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Testing for herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Viral culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Direct fluorescent antibody testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Polymerase chain reaction assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Tzanck prep",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Screening with specific treponemal testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Darkfield microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Direct fluorescent antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Testing for chancroid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Gram stain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - PCR testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Testing for lymphogranuloma venereum (LGV)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11589473\">",
"      - Nucleic acid amplification test (NAAT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Testing for granuloma inguinale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Testing for multiple agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Non-infectious etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Suspected HSV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Primary infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Suspected syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Suspected chancroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1954866\">",
"      Suspected granuloma inguinale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Atypical presentations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      OTHER SEXUALLY TRANSMITTED DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      PUBLIC HEALTH IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Partner notification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7592|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/27/435\" title=\"picture 1\">",
"      Primary syphilis chancre",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/36/15940\" title=\"picture 2\">",
"      Female genital HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/30/43490\" title=\"picture 3\">",
"      Male genital HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/45/23253\" title=\"picture 4\">",
"      Genital lesions chancroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/45/37585\" title=\"picture 5\">",
"      Female LGV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/60/31681\" title=\"picture 6\">",
"      Male LGV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/49/11037\" title=\"picture 7\">",
"      Penile ulcer dark field answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/54/22381\" title=\"table 1\">",
"      GUD clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/15/26875\" title=\"table 2\">",
"      Diagnostic tests in GUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/6/36971\" title=\"table 3\">",
"      Treatment of granuloma inguinale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=related_link\">",
"      Hepatitis B vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18837?source=related_link\">",
"      Laboratory monitoring of patients undergoing treatment for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=related_link\">",
"      Lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_15_12539="In vitro activity against Scedosporium spp";
var content_f12_15_12539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    In vitro activity of antifungals against Scedosporium spp",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        S. apiospermum",
"       </td>",
"       <td class=\"subtitle1\">",
"        S. prolificans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphotericin B",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ravuconazole",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albaconazole",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terbinafine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinocandins",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12539=[""].join("\n");
var outline_f12_15_12539=null;
var title_f12_15_12540="Bacterial tracheitis course";
var content_f12_15_12540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical hospital, intensive care, and ventilation courses of children with bacterial tracheitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Case series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Period of study",
"       </td>",
"       <td colspan=\"2\">",
"        1991-2001",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        1997-2006",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        2000-2005",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No. of cases",
"       </td>",
"       <td>",
"        44 not intubated",
"       </td>",
"       <td>",
"        40 intubated",
"       </td>",
"       <td>",
"        17 (15 intubated)",
"       </td>",
"       <td>",
"        28 (6 intubated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospital days, mean &plusmn; SD (median)",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        11 &plusmn; 11 (7)",
"       </td>",
"       <td>",
"        9.1 &plusmn; 4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PICU days",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        9.1 &plusmn; 8.8 (6.5)",
"       </td>",
"       <td>",
"        2.0 &plusmn; 2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilator days, mean &plusmn; SD (median)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3.2",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        7.5 &plusmn; 5.6 (6)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SD: standard deviation.",
"    </div>",
"    <div class=\"reference\">",
"     1. Salamone FN, Bobbitt DB, Myer CM, et al. Bacterial tracheitis reexamined: is there a less severe manifestation?. Otolaryngol Head Neck Surg 2004; 131:871.",
"     <br>",
"      2. Hopkins A, Lahiri T, Salerno R, Heath B. Changing epidemiology of life-threatening upper airway infections: the reemergence of bacterial tracheitis. Pediatrics 2006; 118:1418.",
"      <br>",
"       3. Huang Y-L, Peng, C-C, Chiu N-C, et al. Bacterial tracheitis in pediatrics: 12 year experience at a medical center in Taiwan. Pediatr Int 2009; 51:110.",
"       <br>",
"        4. Data from subset of 26 intubated cases from January 1995-February 1996 reported by Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14-month experience in a pediatric intensive care unit. Clin Infect Dis 1998; 27:458.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12540=[""].join("\n");
var outline_f12_15_12540=null;
var title_f12_15_12541="Clinical symptoms of selected vitamin deficiencies";
var content_f12_15_12541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical symptoms of selected vitamin deficiencies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deficiency syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Water-soluble vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B1",
"        <br/>",
"        &nbsp;(thiamine)",
"       </td>",
"       <td>",
"        Thiamine pyrophosphate",
"       </td>",
"       <td>",
"        Beriberi - congestive heart failure (wet beriberi), aphonia, peripheral neuropathy, Wernicke encephalopathy (nystagmus, opthalmoplegia, ataxia), confusion, or coma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B2",
"        <br/>",
"        &nbsp;(riboflavin)",
"       </td>",
"       <td>",
"        Flavine adenine dinucleotide",
"       </td>",
"       <td>",
"        Nonspecific symptoms including edema of mucus membranes, angular stomatitis, glossitis, and seborrheic dermatitis (eg, nose, scrotum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Niacin",
"        <br/>",
"        &nbsp;(nicotinic acid)",
"       </td>",
"       <td>",
"        Nicotinamide adenine dinucleotide",
"       </td>",
"       <td>",
"        Pellagra - dermatitis on areas exposed to sunlight; diarrhea with vomiting, dysphagia, mouth inflammation (glossitis, angular stomatitis, cheilitis); headache, dementia, peripheral neuropathy, loss of memory, psychosis, delirium, catatonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B6",
"        <br/>",
"        &nbsp;(pyroxidine, pyridoxal)",
"       </td>",
"       <td>",
"        Transaminase cofactor",
"       </td>",
"       <td>",
"        Anemia, weakness, insomnia, difficulty walking, nasolabial seborrheic dermatitis, cheilosis, stomatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B12",
"        <br/>",
"        &nbsp;(cobalamin)",
"       </td>",
"       <td>",
"        One carbon transfer",
"       </td>",
"       <td>",
"        Megaloblastic anemia (pernicious anemia). Peripheral neuropathy, with",
"        <span style=\"font-family: calibri,sans-serif; font-size: 11pt;\">",
"         impaired proprioception, and slowed mentation.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folate",
"       </td>",
"       <td>",
"        One carbon transfer",
"       </td>",
"       <td>",
"        Megaloblastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biotin",
"       </td>",
"       <td>",
"        Pyruvate carboxylase cofactor",
"       </td>",
"       <td>",
"        Nonspecific symptoms including altered mental status, myalgia, dysesthesias, anorexia, maculosquamous dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pantothenate",
"       </td>",
"       <td>",
"        Coenzyme A",
"       </td>",
"       <td>",
"        Nonspecific symptoms including paresthesias, dysesthesias (\"burning feet\"), anemia, gastrointestinal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin C",
"        <br/>",
"        &nbsp;(ascorbate)",
"       </td>",
"       <td>",
"        Antioxidant, collagen synthesis",
"       </td>",
"       <td>",
"        Scurvy - fatigue, petechiae, ecchymoses, bleeding gums, depression, dry skin, impaired wound healing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Fat-soluble vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Vitamin A",
"        <br/>",
"        &nbsp;(retinol, retinal, retinoic acid)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Vision, epithelial differentiation",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Night blindness, xerophthalmia, keratomalacia, Bitot's spot, follicular hyperkeratosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Vitamin D",
"        <br/>",
"        &nbsp;(cholecalciferol, ergocalciferol)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Prohormone for calcium regulation",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Rickets, osteomalacia, craniotabes, rachitic rosary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Vitamin E",
"        <br/>",
"        &nbsp;(tocopherols)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Antioxidant",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Sensory and motor neuropathy, ataxia, retinal degeneration, hemolytic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Vitamin K",
"        <br/>",
"        &nbsp;(phylloquinone, menaquinone, menadione)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Clotting factors, bone proteins",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Hemorrhagic disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12541=[""].join("\n");
var outline_f12_15_12541=null;
var title_f12_15_12542="Tryptophan and serotonin metabolism";
var content_f12_15_12542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tryptophan and serotonin metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 414px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathways of tryptophan and serotonin metabolism in the carcinoid tumor cell. Patients with the carcinoid syndrome often have increased levels of 5-HIAA excretion in the urine and serotonin in the blood; urinary serotonin excretion is either normal or slightly increased.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12542=[""].join("\n");
var outline_f12_15_12542=null;
var title_f12_15_12543="proportional hazard analysis";
var content_f12_15_12543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Comparison of renal transplant recipient survival according to months on dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 408px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Meier-Kriesche, HU, Kaplan, B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74:1377.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_15_12543=[""].join("\n");
var outline_f12_15_12543=null;
   